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ABSTRACT 
Valproic acid (VPA) was introduced as an antiepileptic in 1967 in France and it has 
become the most prescribed anticonvulsive drug therapy worldwide since then. In the clinic, 
valproic acid is selected to treat absence seizures, myoclonic seizures, generalized tonic-clonic 
seizures, atonic attacks and partial seizures. Epilepsy is the second most common neurologic 
disorder that affects pregnant women (0.5%-1%). Approximately 1 out of 250 pregnant women 
are taking antiepileptic drugs. Valproic acid is designated as a human teratogen, which induces 
major congenital anomalies, facial dysmorphic features, and autistic-like behaviors, which affect 
verbal, cognitive, communicative, and social abilities of affected children.  
We are developing the Japanese rice fish (Oryzias latipes), also known as Japanese 
medaka, as an animal model to study valproate-induced teratogenesis during the period of 
embryogenesis. Fertilized embryos of Japanese rice fish at three developmental stages (group A: 
0-2 dpf; group B: 1-3 dpf; group C: 4-6 dpf) were exposed to VPA (0-80 mM) for 48 hrs. The 
amounts of VPA to cause 50% mortality (LC50), which were observed on 14 day post 
fertilization (dpf), are found to be developmental stage-specific. The LC50 for group A (Iwamatsu 
developmental stage 4-10) is 1.68 ± 1.55 mM which is much lower than the LC50s for groups B 
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(26.45 ±1.64 mM) and C (20.37 ± 3.3 mM) (Iwamatsu developmental stages 17-32). The 
development of the cardiovascular system was disrupted by VPA in each treatment group, 
displaying increased incidence of thrombus, reduced heart rates, and inhibited or delayed onset 
of circulation. The hatching efficiency was also reduced by VPA in each treatment group. The 
higher the concentration of VPA the embryos were treated with, the more severe the results were. 
The earlier developmental stages the treatments were targeted at, the more deleterious the effects 
of VPA were.  
VPA also caused malformation of neurocranial and splanchnocranial cartilages of 
hatchlings that had been exposed prenatally. The length of neurocranium, quadrate, ceratohyal 
and basibranchial 1-3 were all reduced in hatchlings of both groups E (0-2 pdf) and L (4-6 dpf). 
Trabeculae, epiphyseal bar, anterior orbital cartilage and basilar plate displayed reduction in 
length only in hatchlings of group E. In addition, the significant reduction in the linear length of 
polar cartilage and ceratobranchials 1-5 were manifested only in hatchlings of group L. Other 
cartilages remained unaltered in both groups E and L. It was indicated that the length of the 
neurocranium was reduced due to cumulative reduction of the component cartilages.  
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mRNA analyses of nine genes demonstrated that the genes involved with oxidative stress 
remained unaltered after valproate exposure. However, the genes involved with neurogenesis 
(wnt1, otx2 and nlgn3b) and regulation of cell division (shh and ccna2) showed developmental 
stage-specific alteration after valproate exposure.  
This study indicates that valproate is able to induce some phenotypic features in Japanese 
rice fish which are analogous to human fetal valproate syndrome (FVS), and Japanese rice fish 
can be used as a unique alternatively non-mammalian vertebrate model to study 
valproate-induced teratogenesis, including FVS. 
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CHAPTER 1 
INTRODUCTION 
1.1 Valproic acid-induced teratogenesis (fetal valproate syndrome and autistic-like 
behaviors) 
An article in 1992 (Lindhout and Omtzigt, 1992) showed that approximately one out of 
every 250 pregnant mothers uses antiepileptic drugs and a large majority of these use valproate as 
monotherapy or in the part of polytherapy. Valproic acid (VPA, 2-propyl-pentanoic acid), a short 
chain branched fatty acid, was first introduced as an antiepileptic drug in 1967 in France (Perucca, 
2002). In 1978, VPA was put on the market in United States to treat convulsive disorders, and has 
become widely prescribed worldwide since then. In the clinic, VPA is usually the preferred drug 
for treatment of a broad range of seizures, such as absence seizures, myoclonic seizures, 
generalized tonic-clonic seizures, atonic attacks and partial seizures. In addition to its 
antiepileptic effects, VPA is also used as a mood stabilizer in the treatment of psychiatric illnesses 
such as bipolar disorder (depressive-manic phases) (Gyulai et al., 2003; Keck and McElroy, 
2003), and migraine (Calabresi et al., 2007). The mechanisms of action of valproate to treat 
convulsive disorders are suggested to be multiple. Valproate is known to deter neurons consistent
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repetitive firing frequently in culture. Valproate also has an active effect on Na+ currents. It is also 
indicated that valproate can block the NMDA receptor-mediated excitatory currents, and increase 
the levels of GABA in the brain probably through improving GABA synthesis and inhibiting its 
degradation under the effects of valproate on glutamic acid decarboxylase and GABA 
transaminase respectively. Valproate is also approved to inhibit the activity of GAT-1, which is a 
GABA transporter, to facilitate GABA levels in the neurons. Through intensive research, valproate 
is shown as a potent histone deacetylase inhibitor, however, some scientists (Gurvich et al., 2005) 
believed this mechanism of action is where the teratogenic effects of valproate are derived from. 
Besides its common functions, VPA is unconventionally used for the treatment of ischemia (Costa 
et al., 2006), cancer (Blaheta, et al., 2005), Alzheimer’s disease (Qing et al., 2008), latent HIV 
(Lehrman, et al., 2005), terminal blood loss (Alam et al., 2009), and traumatic brain injury (Dash et 
al., 2010). The common adverse effects of VPA in the general population are nausea, vomiting, 
gastrointestinal complaints (abdominal pain and heartburn) and a fine tremor if patients are taking 
a high dose. Other toxic effects of VPA include weight gain, tremor, increased appetite, 
hepatotoxicity, thrombocytopenia and alopecia (Terbach and Williams, 2009). 
Compared with other antiepileptic drugs (AEDs), such as phenytoin, phenobarbital and 
carbamazepine, VPA is designated to be highly toxic if used on pregnant mothers (Dravet et al., 
1992; Kaneko et al., 1999; Kini et al., 2006; Morrow et al., 2006; Diav-Citrin et al., 2008). 
 3 
 
However, VPA has anticonvulsant effects on many different types of epilepsy and relatively absent 
sedative side-effects, compared with carbamazepine and phenobarbitone (Clayton-Smith and 
Donnai, 1995). Therefore, VPA is classified as a Pregnancy Category D drug (Dufour-Rainfray et 
al., 2011) by the American Food and Drug Administration (FDA), which is defined as although 
detrimental effects of VPA on human fetuses are supported by available investigational and 
marketing evidence, potential pros of VPA may be weighed over its potential cons, and it becomes 
a common therapeutic drug used in pregnancies with epilepsy. 
Embryogenesis is subject to the detrimental effects of teratogens (Oxendine et al., 2006). 
Compared with mice and rhesus monkeys, human embryos are more susceptible to VPA 
(Hendrickx et al., 1988; Ehlers et al., 1992; Ehlers et al., 1996; Al Deeb et al., 2000). Development 
of the human embryo can be divided into three crucial periods (Ornoy and Arnon, 1993; Arnon et 
al., 2000; Ornoy, 2003; Ornoy, 2006). The first important period is 0-2.5 weeks after fertilization, 
which is pre-organogenic. Although embryos in the pre-organogenic period are thought to be not 
sensitive to toxicants, highly toxic teratogens may lead pregnancies in this period into abortion or 
still birth. The second significant period, which starts from the 3rd week to the 8th week post 
fertilization, is active organogenesis, and is theorized to be the most susceptible period (Ornoy, 
2009). This theory holds that some toxicants can alter anatomical structures and functions of the 
organ to exhibit the damaging effects. The third critical period is the fetal period which continues 
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until the fetus is born. The earlier the period of the development the embryos were exposed to the 
teratogens, the more severe the deleterious effects were. Therefore, in general, the first trimester of 
pregnancy is the most sensitive period, and pregnant mothers need to take precautions to avoid 
contacting teratogens. Additionally, the longer the exposure continues, the more damaging the 
effects are. Development of the brain continues throughout pregnancy, and hence the brain can 
suffer from adverse effects even if exposure to VPA extends beyond the first trimester (Ornoy 
and Arnon, 1993; Arnon et al., 2000; Ornoy, 2003; Kultima et al., 2004; Ornoy, 2006). It is 
commonly accepted that VPA-induced teratogenic effects are dose and developmental stage 
specific (Ornoy and Arnon, 1993; Arnon et al, 2000; Ornoy, 2003; Ornoy, 2006). Therefore, three 
developmental stages (0-2 dpf, 1-3 dpf, 4-6 dpf) in Japanese rice fish embryos and several 
dosages (2, 5, 10, 20, 40 and 80 mM) were chosen for this project.  
The adverse effects of VPA were first reported in 1980 (Dalens et al., 1980). In 1984, Dr. 
DiLiberti (Diliberti et al., 1984) proposed a specific term "fetal valproate syndrome" to describe a 
well-recognized constellation of major congenital anomalies, dysmorphic features and 
neurodevelopmental retardations of children born to mothers taking valproic acid during 
pregnancy. Due to ethical constraints, VPA-induced teratogenic effects were investigated by 
reported cases in a prospective or retrospective methodology on children born to VPA-treated 
mothers during pregnancy. In addition, some subjects were not willing to participate in the 
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investigation, and, therefore, the results could not rule out a self-selection bias. Therefore, there is 
no sufficient data to draw the conclusive decisions for the phenotypes of children under the 
impacts of VPA-induced teratogenesis. From the available data, the adverse effects of VPA on 
embryonic and fetal development are categorized into three aspects (Ornoy, 2009): (1) Elevated 
risks of major congenital anomalies including neural tube defects, cardiovascular, orofacial and 
digital abnormalities, deformities of eye, skin, abdominal wall, brain, respiratory tract and 
genitourinary systems, etc.; (2) A specific syndrome, ‘Fetal Valproate Syndrome’, presented with 
facial dysmorphic features (figure 2), but also involves damage to other organs, such as the 
neural tube; (3) Neurodevelopmental disorders that affect cognitive, social and verbal skills, 
which lead to stereotypic behaviors, such as autistic-like symptoms. The neurodevelopmental 
disorders are probably due to neural tube defects and other abnormalities which occur in the 
CNS. 
Embryonic and fetal VPA exposure correlates with increased risks of neural, craniofacial, 
cardiovascular, and skeletal birth defects (Nau et al., 1991 and Nau, 1994), and VPA exposure 
induces similar symptoms in a variety of species including amphibians, fish, primates, rodents 
and birds (Dawson et al., 1991; Oberemm et al., 1992; Herrmann, 1993; Kratke et al., 1996; 
Briner et al., 2000; Pennati et al., 2001). Neural tube defects and cardiac defects, the two most 
common congenital birth defects in the human population (Gurvich et al., 2005), also resulted 
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from VPA toxicity with high incidence. Neural tube defects, such as spina bifida, are reported to 
occur with 1-2% incidence in all VPA-treated pregnant mothers, and have often been seen in the 
lumbar and sacral positions (Dalens et al., 1980; Gomez, 1981; Bjerkedal et al., 1982; Robert et 
al., 1983; Lindhout et al., 1992, Omtzigt et al., 1992 and Fried et al., 2004). Lumbosacral 
myelomeningocele was observed at 10-20 times the rate in the general population (Dalens et al., 
1980; Gomez, 1981; Bjerkedal et al., 1982; Robert et al., 1983; Lindhout et al., 1992, Omtzigt et 
al., 1992 and Fried et al., 2004). Neural tube defects can be generated in the third week post 
fertilization. This is generally before the pregnancy can be detected or confirmed. Hence, women 
under treatment with VPA at childbearing age should stop usage of VPA before any planned 
pregnancy (Ornoy, 2009). Besides neural tube defects and cardiac defects, the major congenital 
anomalies also include trigonocephaly, cleft palate and lip, radial ray defects, pulmonary 
abnormalities, coloboma of iris/optic disc and digital defects (Kini, 2006). In general, congenital 
anomalies in babies born to VPA-treated mothers during pregnancy occur at a 2 to 3 times higher 
rate than in the general population (Yerby, 1998; Kozma, 2001). Children with FVS also show 
facial dysmorphic features characterized by broad forehead, thin arched eyebrows with medial 
deficiency, epicanthal folds with infraorbital grooves, flat nasal bridge, broad nasal root, short 
upturned nose, long, smooth and shallow piltrum, downturned mouth, long and thin upper lip, and 
thick lower lip (figure 2) (DiLiberti, et al., 1984; Winter, et al., 1987; Clayton-Smith, et al., 1995). 
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In addition, valproate treatment of pregnant mothers results in low verbal IQ and autistic-like 
disorders (Kini, 2006). As the epidemiological studies indicated, valproate exposure during 
pregnancy is associated with increased incidence of autistic-like behaviors of the offspring 
(Christianson et al., 1994; Rasalam et al., 2005; Bromley et al. 2008).  
Autism spectrum disorder (ASD) is an umbrella term used to define a heterogenous 
neurodevelopmental disorder including classic autism, Asperger syndrome, Rett syndrome, 
childhood disintegrative disorder and pervasive developmental disorder-not otherwise specified 
(PDD-NOS) (Pardo et al, 2007; Lianeza et al., 2010). ASD is described as impairment of cognitive 
abilities and deficiencies in social, communicative, and verbal skills (Gaily et al., 2004). ASD is 
also accompanied by repetitive and sometime self-injurious actions (Landrigan, 2010). ASD 
correlates with attention deficit disorder, and can result in educational problems, especially related 
to verbal intelligence (Gaily et al., 2004). However, difficulties in social interactions or 
relationships are also found in numerous other neurodevelopmental disorders mentioned in the 
Diagnostic and Statistical Manual of  Mental Disorders, fourth edition (DSM-IV) (Bishop et al., 
2007). Thus, use of only behavior criteria to diagnose ASD is not sufficient for diagnosis. Children 
with ASD are usually diagnosed before 3 years of age. Macrocephaly is a commonly diagnostic 
characteristic relevant to autism (Williams et al., 2008). 
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Epidemiological studies indicate increased incidence of ASD worldwide accounting for 
about 1 out of every 150 children in the USA with a male to female ratio of 4.3: 1 (West et al, 2009). 
It is indicated that ASD is a multigenic disease, and environmental insults with deleterious effects 
resulting in gene mutation and epigenetic alterations, particularly when these happen at the critical 
developmental stages (Schanen, 2006), represent significant risk factors in development of ASD.  
In 2006, resperidone was approved by the FDA to treat irritability in children and adolescents with 
ASD, however, resperidone therapy can lead to significant weight gain, metabolic problems, 
tardive dyskinesia and neuroleptic malignant syndrome (Hong et al., 1999; Newcomer, 2005). In 
traditional Chinese medicine, 'Wu Chi' is a specific term to describe the symptoms that are most 
similar to those of ASD (Zhang, 2010). 'Wu Chi' is translated as five retardations, which are 
standing-up retardation, toddling retardation, hair-growth retardation, tooth-growth retardation 
and echolalia retardation. A prescription involving ginseng is assigned to children with the five 
retardations (Zhang, 2010). Ginseng contains many ingredients, such as ginsenosides which are a 
group of triterpenoid saponins and steroid glycosides. Ginsenosides can increase neurogenesis in 
vivo and in vitro under physiological and pathophysiological circumstances (Lu et al., 2010). 
Additionally, ginseng can promote axonal regeneration, and it is also effective in decreasing the 
formation of reactive oxygen species to show its potential neuroprotective function (Rudakewich 
et al., 2001; Ye et al., 2009; Lu et al., 2010). Children with FVS and/or ASD need elaborative care 
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and particular service due to their poor verbal and coordinative skills and musculoskeletal 
deficiency. Children may need extra help at school and even one to one help due to the existent 
learning problems (Kini, 2006). Toilet training may also be highly affected, and affected children 
need significant training to acquire it. Physiotherapy is provided for children with motor 
developmental delay. Surgical intervention before the age of 6 months (Lajeunie, et al., 2001) to 
correct craniosynostosis can also be beneficial for the affected children. 
Since valproic acid is a teratogen, its use during pregnancy is necessary to be considered 
cautiously. The daily dose of VPA during pregnancy is recommended to be below 1000mg and 
divided into 2-3 individual doses. The serum level of VPA needs to undergo minimal fluctuations 
when taking these 2-3 doses per day (Yerby, 2003; Alsdorf and Wyszynski, 2005; Diav-Citrin et 
al., 2008). Dosages above 1000mg of VPA are associated with elevated risks of teratogenic 
effects (Ornoy, 2009). Vitamins of vitamin E and vitamin B family (vitamin B6, B9 and B12), 
especially folic acid, are indicated to have potential protective effects for embryos and fetuses 
(Elmazar et al., 1992; Al Deeb et al., 2000; Yerby, 2003). It is accepted that folic acid is aiding 
rapid cell division to prevent neural tube defects, and hence it is recommended that women take 
4-5 mg per day before planned conception and during the first 2-3 months of pregnancy. For 
women who could not find alternative medications for VPA, it is advised that the potential 
protective reagents, such as vitamin B6, B9, B12 and methionine, are prescribed at 
 10 
 
preconception and during pregnancy. In addition, follow-up examinations are needed to detect 
the status of the fetus before it is born (Ornoy, 2009).  
1.2 Animal Models: 
A spectrum of structural and neurobehavioral anomalies arise in the development of human 
embryos fetuses due to the toxicity of VPA, most appropriately termed as fetal valproate syndrome. 
Intensive researches have been done to determine the potential mechanisms underlying 
VPA-induced teratogenesis, but none of them have provided conclusive results. Human studies of 
FVS are restrained due to ethical constraints. However, several non-human animal models from 
mammals to non-mammals have been utilized to explore the molecular mechanisms of this 
disorder. Multiple mechanisms can lead to damage to embryos exposed to VPA, and certain animal 
models are specialized to study some specific aspects of these processes. Therefore, the choice of 
animal model is of vital importance in the investigation of FVS. Each animal model system has its 
own pros and cons, according to the addressed questions (Cudd, 2005) and comparisons between 
species are informative in investigating gene function and genome evolution (Wang et al., 2006). 
Among the animal models used for mechanistic studies of ASD, rats and mice are the preferred 
models because they are mammals, phylogenetically more close to human, and detailed behavioral 
phenotypic data are available in many of the rodent strains (Halladay et al., 2009). However, 
non-mammalian vertebrates and invertebrates are valuable as high-throughput experimental 
 11 
 
models to investigate how the nervous system performs normally and the effects of various 
environmental stimulants on the nervous system (Halladay et al., 2009). Although the hearts of 
fish and human beings possess essentially different anatomy, their heart morphogenesis, 
vasculogenesis and hematopoiesis are accurately controlled by conserved genetic programs in 
vertebrates (Lambrechts and Carmeliet, 2004). Another advantage of fish models over the 
mammalian models is that the embryos can survive and continue to grow even if the blood 
circulation is completely absent due to small sizes and low metabolism. This allows observation 
for many days, while mammals under the same condition will die early (Lambrechts and Carmeliet, 
2004).  
Japanese rice fish (Oryzias latipes), the Far East cousin of zebrafish, and zebrafish (Danio 
rerio) derived from a common ancestor about 140 million years ago (wittbrodt et al., 2002). Both 
of them are rapidly emerging as important fish models for research on developmental biology and 
toxicology (Wang et al., 2006), and interaction between biological living items and their 
environment. One benefit of applying the fish models rather than mammalian models includes 
their external (outside the body of the mother) fertilization and embryonic development (fertilized 
eggs and larvae), which avoids maternal/placental/fetal influences on embryo development. 
Another benefit is the transparent chorions covering the embryos. Therefore, investigators can 
observe the developmental conditions of embryos, such as their onset of circulatory system and 
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normal/abnormal heart formation, directly (Wu et al., 2008). Additionally, fish models possess the 
characteristics of easy availability, low maintenance cost, short life cycle and their accessibility to 
studies of the gene function (Wittbrodt et al., 2002; Furutani-Seiki and Wittbrodt, 2004). Therefore, 
fish models are currently emerging as alternatives to mammalian models. Large-scale mutagenic 
screens in zebrafish and Japanese rice fish have revealed several orthologue genes that are highly 
correlated to those involved in human genetic diseases (Naruse et al., 2004).  
In zebrafish, VPA-induced teratogenic effects have been investigated by many 
investigators and the data were almost identical with other models. More specifically, retardation 
and cessation of embryonic development, yolk and cardiac edema, brain deformities, 
malformations of eye, otoliths and somites, cardiovascular defects, skeletal deformities including 
shortened and bent tail (Herrmann, 1993; Selderslaghs et al., 2009) were observed in zebrafish 
embryos and hatchlings after developmental VPA exposure. However, VPA analogs such as 
valpromide were found to be weak in producing teratogenic activity in zebrafish compared to VPA 
alone (Herrmann, 1993; Gurvich et al., 2005). S-valproate is associated with a significant increase 
in intersomitic vessel defects in zebrafish embryos (Isenberg et al., 2007). Moreover, VPA 
interfered with liver and exocrine pancreas formation in zebrafish during embryogenesis (Farooq 
et al., 2008). Furthermore, VPA suppresses seizure-like behavior and improves learning ability in 
adult zebrafish treated with pentylenetetrazol (Lee et al., 2010). The teratogenic effects of VPA in 
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zebrafish are thought to be mediated through the inhibition of HDACs (histone deacetylases) 
(Gurvich et al., 2005; Menegola et al., 2006; Cao et al., 2009). Several laboratories have 
established zebrafish as an applicable animal model to study mechanisms of VPA toxicity and/or 
autism spectrum disorders (ASDs), and developing another fish model for comparative studies can 
increase persuasive abilities of the results and allow opportunities for improvement (Wang et al., 
2006). Besides genome size strength of Japanese rice fish if compared with genome size of 
zebrafish (800 Mb in Japanese rice fish and 1700 Mb in zebrafish), only the Japanese rice fish and 
its nearest relative, Oryzias curvinotus, are the known non-mammalian vertebrates where the sex 
determining gene DMY has been identified and characterized (Matsuda, 2005; Matsuda et al., 
2002, 2003). Therefore, Japanese rice fish may be an excellent alternative non-mammalian animal 
model if we are looking forward to verifying what, if any, effects the gender might have in VPA 
toxicity. Japanese rice fish exhibit another advantage over zebrafish due to the fact that their 
cardiovascular development conforms mostly to the common embryonic circulatory pattern 
investigated in other vertebrates including the human, whereas the zebrafish has a distinctly 
different pattern (Fujita et al., 2006). 
In Japanese rice fish, the embryonic development of the cardiovascular system has been 
thoroughly studied by several investigators (Iwamatsu, 2004; Fujita, 2006). Since Japanese rice 
fish grow distinct yolk veins, these may be exploited as target sites to study the effects of VPA on 
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the cardiovascular system (Wang et al., 2006).  Therefore, the structure and development of the 
cardiovascular system needs to be understood if we intend to know the significance of 
time-dependent treatments. Table 3 outlines every developmental phase of the cardiovascular 
system in the embryos of Japanese rice fish. Japanese rice fish embryos after Iwamatsu stage 25 
can be compared to fetuses, since these embryos (Iwamatsu stage 25 and onwards) have a 
well-developed cardiovascular system, several organs including the brain (organogenesis) and 
pectoral fin buds share corresponding features with human fetuses (Hu et al., 2006). 
1.3 Metabolism of valproic acid 
80-90% of consumed VPA binds to plasma proteins and is conjugated in the liver of 
human beings (Kini, 2006). VPA exhibits its toxicity to the fetus and becomes concentrated in 
the fetal compartment by diffusion across the placenta instead of placental binding (Nau H.1982; 
Albani et al., 1984; Bailey and Briggs, 2005). The highest ratio of VPA serum concentration in 
fetuses to that in mothers can be 6, and mean ratios are 1.4-2.4 (Ornoy, 2009). This means that 
the fetus is exposed to a much higher concentration of VPA than the mother (Clayton-smith and 
Donnai, 1995; Ornoy, 2009). In 1984, Albani (Albani et al., 1984) reported that low 
concentrations of VPA are excreted into human milk (less than 5% of the weight-adjusted daily 
dose that taken by mothers) (Von et al., 1984; The WHO Working Group, 1988). Therefore, 
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lactation and breast feeding by VPA-treated mothers is allowed (Albani et al., 1984; Von et al., 
1984; The WHO Working Group, 1988).  
1.4 Potential Molecular Mechanisms of toxicity of VPA and autism: 
The mechanism(s) by which VPA induces anticonvulsant, antimanic, and teratogenic 
effects are unknown, but some reports suggest that the medical and the teratogenic effects of VPA 
are different. Several studies indicate that teratogenic effects of VPA may be related to folic acid 
deficiency, induction of oxidative stress, and inhibition of HDAC (Ornoy, 2009). Furthermore, 
VPA influences gamma aminobutaric acid (GABA) synthesis and breakdown (Loscher, 2002; 
Calabresi et al., 2007), reduces de novo inositol synthesis (Agam et al., 2002; Shaltiel et al., 2007) 
and ion channel activity, causes inositol triphosphate depletion (Berridge et al., 1989; Eickholt et 
al., 2005; Shimshoni et al., 2007), regulates fatty acid signaling and turnover (Bazinet et al., 2006), 
and activates the mitogen activated protein (MAP) kinase pathway (Hao et al., 2004). VPA is also 
associated with carnitine depletion (Coulter, 1991), which affects mitochondrial fatty acid 
metabolism leading to hepatotoxicity, and hepatocellular necrosis can happen. Syndromic ASD 
accompanied by tuberous sclerosis, neurofibromatosis or macrocephaly presents abnormal 
cellular/synaptic growth rate, and this is because mTOR/PI3K pathway was activated by mutated 
TSC1/TSC2, NF1, or PTEN (Pardo and Eberhart, 2007; Bourgeron, 2009). Neurexin, which is a 
presynaptic protein, interaction with the postsynaptic adhesion molecule neuroligin, is necessary 
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for synaptic maturation and synaptogenesis (Bourgeron, 2009). Neuroligin then interacts with the 
scaffold protein Shank, which activates other scaffold proteins, such as PSD-95. This regulates 
AMDA, NMDA and GABA receptors in the postsynaptic membranes and affects the balance 
between excitatory and inhibitory electrical currents (Sudhof, 2008; Bourgeron, 2009). This 
nrxn-nlgn-shank pathway is, therefore, suggested to be related to the causes or symptoms of ASD. 
In addition, signaling molecules, such as neurotrophin (for example, brain-derived neurotrophic 
factor (BDNF)), Reelin, hepatocyte growth factor, and neurotransmitters such as serotonin and 
glutamate, are also thought to be involved in the pathogenesis of ASD (Pardo and Eberhart, 
2007). VPA-induced teratogenesis probably derives from the interactions between VPA and 
several genes and proteins in humans at some certain critical developmental stages. These 
interactions alter the expression of several genes and result in modification of protein function.  
In our study, we examined several genes to investigate their expression pattern under the 
treatment of VPA. Catalase, gst and gr are oxidative stress-related genes, and were used to 
investigate whether VPA has a toxic effect through an oxidative stress-related pathway. The 
another five genes, nlgn3b, iro3, wnt1, otx2, shh, are expressed in the brain of Japanese rice fish 
embryos and are involved in neurogenesis. The other two genes, cyclin a2 and shh, are 
associated with cell division. Most of these genes were reported to be expressed in Japanese rice 
fish embryos during morphogenesis (Kage et al., 2004: Wu et al., 2008, 2011), and are altered by 
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valproate in human and rat (Graf et al., 1998; Bambini-Junior et al., 2011; Tung and Winn, 2011). 
Iro3, otx2, shh, wnt1 are transcription factors expressed in the neural tube of Japanese rice fish 
embryos at early developmental phases and are implicated importantly in brain morphogenesis 
(Kage et al., 2004). The gene, iro3, belongs to the Iroquois family of homeoproteins and is 
constitutively expressed in vertebrates, flies, and nematodes (Gomez-Skarmeta and Modolell, 
2002). In zebrafish, iro3 has been shown to be required for correct organizer function (Kudoh 
and Dawid, 2001). The gene, otx2, is recognized as an early head-domain marker (Blitz and Cho, 
1995; Pannese et al., 1995). The wnt1 gene family involves several signaling molecules showing 
many biological effects in the formation of the mesoderm of the gastrula (Christian and Moon, 
1993; Hoppler et al., 1996; Hoppler and Moon, 1998) and the neural ectoderm (McGrew et al., 
1995, 1997) at the dorso-ventral axis during cleavage stages (Moon and Kimelman, 1998). The 
gene, shh, plays a critical role in cell proliferation, differentiation and patterning by activating the 
hedgehog signaling pathway. The shh gene is expressed in several organs, including the lung 
(Bellusci et al., 1997), the fin ray (Laforest et al., 1998), the epidermis (Sire and Akimenko, 
2004), somites (Fan and Tessier-Lavigne, 1994; Johnson et at., 1994; Fan et al., 1995), limb and 
fin buds (Krauss et al., 1993; Laufer et al.,1994), and teeth (Bitgood and McMahon, 1995; Iseki 
et al., 1996; Koyama et al., 1996). The cyclins, and their cyclin-dependent kinase partners the 
Cdks, are the basic components of the machinery that regulates the passage of cells through cell 
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cycle. These selected genes were used to investigate the potential bio-signaling pathways 
involved in VPA-induced pathogenesis. 
1.5 Hypothesis and objectives of the study:  
It was revealed by human epidemiological studies that embryos in utero exposed to VPA 
during the first trimester (first 12 weeks) of pregnancy are associated with high risk of 
VPA-induced teratogenesis including fetal valproate syndrome (FVS) and autism spectrum 
disorders (ASDs) in the offspring (Christianson et al., 1994). This indicates that VPA-induced 
deleterious effects are developmental stage-dependent. Three developmental stage groups (0-2 dpf, 
1-3 dpf, 4-6 dpf) of Japanese rice fish embryos were chosen to investigate the effects of VPA. 
Differentiation and migration of neural crest cells (NCCs) during embryogenesis determines 
craniofacial cartilages and bones formation. Therefore, any alteration in embryonic differentiation 
and migration of NCCs may affect the structure of craniofacial cartilages and bones (Wang et al., 
2006). In Japanese rice fish, the excision of the neural crest on embryos at the neurula stage will 
lead to defects in craniofacial cartilages and bones (Langille and Hall, 1988). During 
embryogenesis, the heart initiates function as the first organ prior to the advancement of other 
organs, and normal development and function of the cardiovascular system is very crucial for the 
growth of embryos of Japanese rice fish. Since embryos are supplied with nutrients that come from 
yolk by circulation, any disruptions occurring to circulation/circulatory system by VPA will 
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prohibit embryos from normal development (Hu et al., 2006). Development of the cardiovascular 
system and the craniofacial cartilages of fish models are subject to exogenous chemicals, such as 
alcohol (Wang et al., 2006). Children affected with FVS have congenital major malformations 
occurring in the cardiovascular system and the neurological system with characteristic facial 
dysmorphisms. Therefore, cardiovascular and craniofacial features were investigated and used as 
the phenotypic parameters to study VPA-induced teratogenesis in Japanese rice fish. 
The present study had three main objectives. First, to determine the validity of VPA as a 
teratogen in Japanese rice fish by comparison with those effects previously observed in 
VPA-treated zebrafish and mammalian models. Second, the molecular mechanisms that are 
suggestive to be related to VPA-induced teratogenesis (ASD and/or FVS) in humans will be 
investigated by studying gene expression patterns in Japanese rice fish. Finally, the applicability of 
the Japanese rice fish as an alternative animal model for future research on FVS and/or ASD will 
be studied. In this regard we have analyzed several morphological parameters including 
neurocraniol and splanchnocranial cartilages and mRNA expression patterns of several genes 
which are expressed during Japanese rice fish embryogenesis (Wu et al., 2008, 2011). Our data 
indicate that VPA is able to induce teratogenic effects in Japanese rice fish. These include yolk 
edema, malformed neurocranium and splanchnocranium, decreased hatching efficiency, reduced 
heart rate, increased thrombi formation, inhibited onset of blood circulation, and altered 
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expression of several genes, the orthologs of which have been shown to have the potential to 
induce ASD in humans. Japanese rice fish (Oryzias latipes) embryo-larval development has been 
used as a unique non-mammalian model to study the molecular mechanism of FVS. 
Epidemiological studies in humans indicate that VPA exposure during pregnancy induces higher 
incidence of autism in the offspring (Christianson et al., 1994; Rasalam et al., 2005; Bromley et al., 
2008). Therefore, teratogenic studies with VPA may throw light on understanding the mechanisms 
associated with ASD. 
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Figure 1: Chemical structure of valproic acid (Chateauvieux, et al., 2010) 
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Table 1: Specific features related to fetal valproate syndrome (Kini, 2006) 
 
Neural tube defects 
Trigonocephaly 
Radial ray defects 
Pulmonary abnormalities 
Coloboma of iris/optic disc 
Low verbal IQ 
Autism and autism spectrum disorder 
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Figure 2: Child with facial dysmorphic features of FVS: trigonocephaly, which has been 
surgically repaired, broad forehead, thin arched eyebrows with medial deficiency, flat nasal 
bridge, infraorbital grooves, broad nasal root, short anteverted nose, long, shallow, and smooth 
philtrum, long and thin upper lip, and thick lower lip (Kini, 2006). 
 
broad forehead 
thin arched eyebrows with 
medial deficiency flat nasal bridge 
broad nasal root 
infraorbital grooves 
short anteverted nose 
long, shallow and smooth philtrum 
long and thin upper lip 
thick lower lip 
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Table 2: Anomalies associated with valproate exposure (Kini, 2006) 
 
Neural Tube Defects Congenital Heart Defects Limb Defects 
Spina bifida 
Anencephaly 
Ventricular septal defect 
Atrial septal defect 
Aortic stenosis 
Patent ductus arteriosus 
Anomalous right pulmonary artery 
Radial ray defect 
Polydactyly 
Split hand 
Overlapping toes 
Camptodactyly 
Ulnar or tibial hypoplasia 
Absent fingers 
Oligodactyly 
Genitourinary Defects Brain Anomalies Eye Anomalies 
Hypospadias 
Renal hypoplasia 
Hydronephrosis 
Duplication of the calyceal system 
Hydranencephaly 
Porencephaly 
Arachnoid cysts 
Cerebral atrophy 
Partial agenesis of corpus callosum 
Agenesis of septum pellucidum 
Lissencephaly of medial sides of occipital lobes 
Dandy-Walker anomaly 
Bilateral congenital cataract 
Optic nerve hypoplasia 
Tear duct anomalies 
Microphthalmia 
Bilateral iris defects 
Corneal opacities 
Abdominal Wall Defects Respiratory tract anomalies Skin abnormalities 
Omphalocoele Tracheomalacia 
Lung hypoplasia 
Severe laryngeal hypoplasia 
Abnormal lobulation of the right lung 
Right oligaemic lung 
Capillary haemangioma 
Aplasia cutis congenita of scalp 
  *Rare structural abnormalities are shown in italics.
 25 
 
Table 3: Phenotypic features of the cardiovascular system development of Japanese rice 
fish (Iwamatsu, 2004)  
 
Iwamatsu 
stage 
Hpf Description 
22 ~38  The heart becomes visible. 
23 ~41 The blood vessels (Cuvierian ducts and vitello-caudal vein or marginal 
vein) and the intermediate cell mass (ICM) or blood island become 
obvious. 
24 ~44  The hearts begins beating with very low heart rate (32-64 beats/min), and 
the embryonic erythrocytes and hemangioblasts are gathered in ICM 
during this period. 
25 ~50 The heart rate rises (70-80 beats/min) and the globular blood cells come 
out from the ICM (onset of circulation). 
28 ~64 The blood cells display flattenly. 
29 ~74 The embryonic heart starts to differentiate into atrium, ventricle, sinus 
venosus and bulbous aorta. 
30 ~82 Arteries starts to branch to provide trunk muscles, gills and brain with 
blood. 
34 ~121 The circulation to the pectoral fin takes place. 
36 ~144 The looping of heart is accomplished. 
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CHAPTER 2 
MATERIALS AND METHODS 
The institutional animal care and use committee (IACUC) of the University of 
Mississippi has approved all of the experimental animal protocols. Methods of animal 
maintenance, embryo collection, alcian blue staining of hatchlings, RNA extraction, purification 
and semi-quantitative relative (RT-PCR) techniques have been previously described 
(Dasmahapatra et al., 2005; Wang et al., 2006, 2007; Hu et al., 2008, 2009; Wu et al., 2008, 
2011). The research procedure used Japanese rice fish embryos and hatchlings. Each group 
consisted of 8-16 embryos and each experiment was repeated 3-5 times. 
2.1. Fish maintenance: Adult males and females (orange-red variety, d-rR strain) Japanese 
Rice fish  (Oryzias latipes) were maintained in a AHAB Stand-Alone recirculating system 
(Aquatic Habitats), which is a Japanese Rice fish housing system, at 25 ± 1 °C, 16L:8D 
photoperiod in balanced salt solution (BSS, 17 mM NaCl, 0.4mM KCl, 0.3 mM MgSO4, 0.3 
mM CaCl2 in nano-pure water), keeping salinity at 1-1.2 ppt and pH 7.4. The Japanese rice fish 
were fed with a combination of tetramin flakes (Tetra) and live brine shrimp twice a day. The 
brine shrimp eggs were purchased from Ocean Star International, Inc. (10880 Wiles Road,
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Coral Springs, FL 33076). Brine shrimp eggs hatched after being maintained in salty water (30 
g/L NaCl) and aerated for 48 hrs at 25 ± 1 °C. 
2.2. Treatments used to investigate the lethal concentrations of valproic acid and the 
effects of valproic acid on hatching efficiency and on the cardiovascular system at three 
different time points: The clustered fertilized embryos were collected and separated manually 
by gently rubbing over a 20.3 cm (diameter) × 2.5 cm (depth) brass sieve (Fisher Scientific 
Company) with openings that are 300 µm. The status of each embryo was checked under a 
phase contrast microscope (AO Scientific Instruments, Model: 1820) and the viable embryos 
were kept for future research. The developmental stages of embryos were identified and 
categorized as Iwamatsu described previously (2004). Three developmental stages of Japanese 
rice fish embryos were tested (A group: 0-2 dpf; B group: 1-3 dpf; C group: 4-6 dpf). Fertilized 
embryos with intact chorion within ~4h, 24 h (~1 day) or 96 h (~4 day) post fertilization (dpf) 
were exposed to VPA (0-80mM) for 48 hours with a one time change of  medium at the same 
concentration of VPA at 24 h. After 48 hrs exposure, the embryos were transferred to clean 
hatching solution in 48 well culture plates (one embryo/well/ml hatching solution) without VPA 
and with a 50% static renewal of the medium per day until 14 dpf. The hatching solution 
contained 0.0002% methylene blue (MB) to prevent fungal growth.  
2.3 Lethal concentrations of valproic acid determined on embryos of Japanese rice fish 
 28 
 
exposed at three different developmental stages: The unhatched embryos were maintained in 
the 48 well culture plates until 14 dpf. The embryos without heartbeats on 14 dpf would be 
considered dead. The LC50 values (mortality of embryos) for VPA in three different 
developmental stage groups were obtained by 14 dpf. 
2.4 VPA effects on hatching efficiency of Japanese rich fish: Under the experimental 
conditions of 25±1°C, 16L: 8D light cycle mentioned above, embryos began hatching after 7 
dpf. The development of the embryos treated with VPA was comparatively delayed, and 
therefore the alive but unhatched embryos were maintained in 48 wells culture plates until 14 
dpf. The embryos that hatched earlier were recorded. The final hatching efficiency (cumulative 
hatching incidence of embryos at each developmental stage) was determined on 14 dpf. 
2.5 Analysis of deleterious effects of VPA on the cardiovascular system of Japanese rice 
fish: The cardiovascular system (circulation status and development of thrombi) of the embryos 
was examined on 6 dpf under the phase contrast microscope (AO Scientific Instruments) with a 
50% static renewal of VPA free medium each day. The heart rates and circulation status can be 
investigated according to the developmental stage maps that were established by Iwamatsu 
(2004). The embryos were in circulating state when there was blood flowing through any of the 
circulation vessels. When blood was not flowing even through a single vessel the embryos were 
considered as in non-circulating state. The heart rate in beats per minute of each embryo was 
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determined on 6, 7 and 8 dpf in ovo. 
2.6. Morphometric analysis of craniofacial cartilages in Japanese rice fish hatchlings 
exposed to VPA. 
2.6.1. Treatments: The alive embryos were obtained and separated according to the method 
described above (Paragraph 2.2). Embryos at two different developmental time points (Early 
developmental stage: 0-2 dpf; Late developmental stage: 4-6 dpf ) were transferred to 48 wells 
culture plates and exposed to 1 ml hatching solution or 1ml  hatching solution with 2 mM VPA 
(1 embryo/ml/well). Exposure was for 48 hrs with changing of the corresponding medium at 24 
hrs. After 48 hrs exposure, the embryos were washed twice with clean hatching solution and 
maintained in 1 ml hatching solution until hatching with a 50% static daily renewal of clean 
hatching solution. Ordinarily, the embryos begin to hatch after 7 dpf. Since VPA can lead to 
developmental delay, embryos were maintained in hatching medium until 14 dpf.  To avoid 
post hatching growth, within 24 hrs after hatching the hatchlings were preserved in 4% 
paraformaldehyde.  
2.6.2. Cartilage staining: The neurocranial cartilages of hatchlings were stained with 0.1 % 
Alcian blue (Sigma-Aldrich, St. Louis, MO) following the protocol used in Zebrafish by Carvan 
et al. (2004) with minor modifications. After hatching, the hatchlings (8 or 16 per group) were 
anesthesized in MS222 (Tricaine methanesulfonate) (0.1% in hatching solution: Sigma-Aldrich, 
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St. Louis, MO), and then fixed in 4% paraformadehyde (Sigma-Aldrich, St. Louis, MO) in 
phosphate-buffered saline (PBS) with 0.1% Tween 20 (PBT) at 4 0C for 24 hrs. The fixed 
hatchlings were washed with nanopure water twice and then treated with 5% TCA for 10 mins. 
The TCA-treated hatchlings were washed briefly with acid ethanol (0.37% HCl, 70% ethanol), 
and stained in 0.1% Alcian blue for 6 hrs. Excess stain was washed away with ethanol. 1% 
trypsin was used to digest the muscle tissues of the stained hatchlings at 37 0C for 3-4 hrs until 
all the muscles disappeared as determined by the absence of dark spots in the view as it 
appeared under the phase contrast microscope. The samples were finally preserved for 
long-term use in 70% glycerol at 4 0C after washing with glycerol-KOH (50% glycerol and 
0.25% KOH). 
2.6.3. Morphometric analysis: The neurocranial and splanchnocranial cartilages, stained with 
Acian blue, were investigated under an Olympus BX 40F-3 microscope to analyze the effects of 
VPA exposure during embryonic development. The entire neurocranium and splachnocranium 
were captured as photomicrographs using the microscope at fixed magnification (100X/40X). 
Most of the photomicrographs were captured at 100X magnification, and some were at 40X 
magnification. The linear lengths of the cartilages of the neurocranium and the 
splanchnocranium were measured using imaging software (Media Cybernetics, Silver Springs, 
MD). The length of the cartilages were calculated by pixel values and multiplying by the 
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corresponding magnification factor. After staining with Alcian blue, the ethmoid plate (EP) with 
lamina orbitonasalis, paired trabeculae (TB), anterior orbital cartilage (AOC), posterior orbital 
cartilage (POC), epiphyseal bar (EB), basilar plate (BP) with anterior (ABC) and posterior  
(PBC) basicranial commissures, hypophyseal plate (HP) with paired polar cartilages (PC), and 
auditory capsules in the neurocranium could be visualized. In the splanchnocranium, Meckel’s 
cartilage (MC), pterygoid processes (PT), quadrate (QU), hyosymplectic (HYS), hyoid (HYO), 
basihyal (BH), ceratohyal (CH), 4 basibranchials (BB), 3 pair hypobranchials (HBR), 5 pair 
ceratobranchial (CBR), 4th epibranchial (EBR) and 4th hypobranchial (HBR) are also clearly 
identifiable (Figures 6-7). The nomenclature of the cartilages used in this communication was 
defined by Langille and Hall (1987). In the present experimental conditions, generally embryos 
of group E exposed to 5 mM VPA and above, were unable to hatch even after 14 dpf. In group 
L, less than 25% of embryos exposed to 5 mM VPA were able to hatch. Therefore, only data for 
hatchlings of groups E and L exposed to 2mM VPA prenatally are presented. The individual 
cartilages and the entire neurocranium were used for morphometrical analysis. In the 
neurocranium, EP, AOC, EB and BP are linear, and therefore were measured directly. TC and 
PC are not always of equal size in the left and right sides, and hence both sides were measured 
individually and an average was calculated. The linear length of ABC was measured from the 
anterior end of the ABC to the head of the notochord on both sides and then averaged. In the 
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splanchnocranium, QH, BH, CH, BB (1-4), CBR (1-4) are linear and were measured directly. 
BB 1-3 can not be identified visually, and thus the total length of BB 1-3 was considered as one 
parameter. BB 4 is separated from BB 1-3 visibly, and thus was measured individually. The 
lower jaw (MC) is curved, and therefore the length was determined from the joint points of two 
parts of the lower jaw (MC) to the midpoint of an imaginary line drawn linking the lower jaws 
ends. The 5th CBR is also curved and its length was decided as the distance between the 
meeting points of the left and right 5th CBRs and the central of an imaginary line drawn to link 
the anterior end of the pharyngeal teeth. The POC, auditory capsule, PBC in the neurocranium, 
and PT, HYS, HYO in the splanchnocranium are irregularly shaped and consequently were not 
used for morphometric analysis (figures 6-7).  
2.7. Biochemical analysis of Japanese rice fish embryos exposed to valproic acid 
RNA was extracted from the intact embryo (embryos with yolk) by Trizol reagent 
(Wang et al., 2007). The primers used for rRT-PCR of mRNAs of several genes (catalase, gr, 
gst, iro3, nlgn3b, otx2, wnt1, shh and ccna2) are mentioned in Table 8. 
2.7.1. Treatments: Japanese rice fish embryos were exposed to varying concentrations of VPA   
at three different time points of development (A group: 0-2 dpf; B group: 1-3 dpf; C group: 4-6 
dpf). Exposure was discontinued after 48 hours following a one time renewal of the medium at 
24 h. In addition to controls, embryos in A group were exposed to 1 mM and 2 mM VPA, and in 
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B and C groups were exposed to 2 mM, 5 mM. For RNA extraction, the embryos were washed 
with hatching solution twice and homogenized immediately after completion of the 48 hr 
exposure to VPA. 
2.7.2. Isolation of RNA: The total RNA was extracted from Japanese rice fish embryos by 
using Trizol reagent (Invitrogen, Carlsbad, CA), following the manufacturer's instruction. 0.5 
ml of Trizol was added to each tube, which contained 6-8 embryos from the same treatment 
group. These were then homogenized and centrifuged (Labnet International, Inc., Edison, NJ; 
model: PRISM R) at 12,000 X g for 20 mins at 4 0C. The upper clear phase was removed to a 
1.5 ml clean centrifuge tube, to which was added 0.25 µl of isopropanol (Sigma-Aldrich, St. 
Louis, MO, USA). The mixture was incubated at room temperature for 10 minutes, and 
centrifuged again at 12, 000 X g for 20 mins at 4 0C. The precipitate was cleaned with a 1 ml 
75% ethanol wash. DNA from the washed RNA was removed by treating the samples with 
DNase I (Promega, Madison, WI). The final 50 ul volume containing one unit of DNase I, 1 X 
transcription buffer (50 mM Tris-HCl, 75 mM KCl, 3 mM MgCl2, 0.5 mM MnCl2) and 40 U of 
RNAsin (Promega, Madison, WI) was added to the 75% ethanol-washed RNA.  After 
incubation at 37 0C for 20 mins, the DNase I was removed by the same methods of Trizol 
precipitation. The purified RNA was stored at -80 0C. The concentration of RNA was obtained 
with an Eppendorf Biophotometer. The purity of the RNA was determined by distinct 18S and 
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28S ribosomal RNA using 1% agarose gel electrophoresis with 0.1% ethidium bromide, and the 
ratio of absorbance at wavelength 260 nm and at 280 nm is over 1.5. 
2.7.3. Semi-quantatative RT-PCR: A first strand cDNA synthesis protocol (Invitrogen, 
Carlsbad, CA) was followed to synthesize cDNA by using 1 µg of DNA-free total RNA. The 
cDNA was synthesized in a 20 ml reaction volume that included 4 µl 5 X buffer (composition), 
1 µl 10 mM dNTPs, 1 µl 10 mM DTT, 1 µl oligo dT and 200 U of superscript Ш RNA 
polymerase (Invitrogen, Carlabad, CA) at 50 0C for 1 h. 1 µl of synthesized cDNA in a final 
volume of 20 µl was used to detect the expression levels of several transcription factor mRNAs 
by semi-quatitative PCR. The 20 µl reaction mixture contained 10 µl of 2 X buffer (composition) 
(Qiagen, Valencia, CA), 1 µl cDNA, 50 pM each of forward and reverse primers of the target 
genes and 50 pM each of forward and reverse primers of the internal control (beta-actin).  The 
amplification reaction for semi-quatitative PCR was carried out in a PTC-200 Peltier Thermal 
cycler (Opticon 2 MJ Research, Reno, NV).  30 cycles of denaturation at 94 0C for 30 s, 
annealing at 60 0C for 1 min and extension at 72 0C for 2 mins followed initial denaturation at 
94 for 2 mins. The final step was extension at 72 0C for 7 mins. 5 µl of the reaction product was 
separated using 2% agarose gel electrophoresis (100 voltages; room temperature) containing 
0.1% ethidium bromide (µg/ml) and two bands, one of the target gene and one of the internal 
control,  appeared under 290-365 nm ultraviolet light. The gel electrophoresis pictures were 
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taken using a Versadoc Imaging System (BioRad, Hercules, CA; Model: 3000) and the band 
intensities of the target gene and the internal control were determined using image analysis 
software (Quantity One, BioRad). The results were expressed as the ratio of relative band 
intensity of target gene to the band intensity of the β-actin gene. 
2.8. Statistical analysis: LC50s were calculated from transformed data ( log valproate 
concentration) using a nonlinear regression (curve-fit) program (Graph-Pad Prism, version 5, 
San Diego, CA). All other data (thrombi, vessel circulation, heart rate and hatching efficiency) 
were analyzed by using one way ANOVA followed by Tukey's multiple comparison post-hoc 
test. The rRT-PCR data were transformed (log ratio of band intensity of target gene to the band 
intensity of the β-actin gene) before analysis. For skeletal cartilages endpoint measurement, the 
data were analyzed by unpaired Student's t test. The results were expressed as mean ± SEM of 
3-4 independent experiments and P<0.05 was considered significant.
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CHAPTER 3 
RESULTS 
3.1 Lethal concentration of valproic acid on Japanese rice fish developmentally and 
prenatally exposed at different developmental stages. 
Three developmental stages of Japanese rice fish embryos were set as three different 
treatment groups and tested (A group: 0-2 dpf; B group: 1-3 dpf; C group: 4-6 dpf). Fertilized 
embryos of Japanese rice fish with intact chorion were exposed to valproate (0-80 mM) for 48 
hrs during these three developmental stages with a one time change of the medium at 24 hr and 
then transferred to clean hatching solution without valproate. On day 14 post fertilization (dpf), 
the calculated LC50 values for valproate as determined from three separate independent 
experiments (group A has six separately independent experiments, groups B and C has three 
separately independent experiments) were 1.68 ± 1.55 mM with 0-2 dpf (group A) , 26.45 ± 1.64 
mM with 1-3 dpf exposure (group B) and 20.37 ± 3.3 mM with 4-6 dpf exposure (group C) 
(Table 3). The survival rates of embryos were severely reduced in groups B and C when the 
concentration of VPA was 20 mM or higher. Additionally, the embryos died completely in group 
A if the VPA concentration reached 10 mM. When the concentration was 40 mM or higher, 75%
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- 100% of embryos in all groups died. It is worth noting that group A is more sensitive to the 
toxicity of VPA since this group showed 75%-100% mortality rate occurring in all experiments at 
the concentrations of 5 mM or higher. The LC50 of group A is much lower than that of groups B 
and C, suggesting that the VPA toxicity is developmental-stage specific (Figure 3). 
3.2 Effects of vaproic acid on hatching efficiency of Japanese rice fish at different 
developmental stages. 
In our facility, the control embryos initiated hatching at 7+ dpf. The hatching efficiency 
of the embryos was altered by VPA and found to be dose-dependent. The embryos of groups A, 
B and C were able to hatch (>75%) if they were exposed to VPA concentrations below or equal 
to 2mM. However, when embryos were exposed to 5 mM valproate, none of the group A 
embryos, below 50% of group B embryos and below 5% of group C embryos were able to hatch 
successfully (Figure 4). It is notable that group B embryos with 5 mM VPA treatment had a much 
higher incidence in hatching efficiency comparing with group A or C exposed to the same 
concentration of VPA. The reason for this will be discussed in the next chapter.  None of the 
embryos treated with 10 mM VPA in all groups was able to hatch.  Compared with controls, 5 
mM or higher concentration of VPA was able to reduce the hatching efficiency significantly in all 
groups. 
3.3 Morphometric analysis of Japanese rice fish exposed to valproic acid at different 
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developmental stages. 
3.3.1 VPA effects on the cardiovascular system 
The cardiovascular development (heartbeat, circulation status and thrombus formation) of 
the embryos was examined on day 6 post fertilization (for group A 4 days after, for group B 3 
days after, and for group C immediately after valproate removal from the medium). 
3.3.1.1 VPA effects on heart beat 
Heart rates were determined for three consecutive days (6-8 dpf) in all three groups. 
Usually, the control embryos start hatching after 7 dpf. To avoid hatching effects, we have 
restricted our heart rate observations in ovo from 6 to 8 dpf. Here again a dose-dependent 
reduction in heart rate in all groups was observed. Moreover, embryos exposed to 10 mM or 
higher concentration of VPA in group A, and embryos exposed to 80 mM VPA in groups B and C, 
displayed no heart beat in the 6-8 dpf period (Figure 5.1-5.3). In group A, the heart rate was 
significantly reduced in embryos exposed to 5 mM. Heart rate was not reduced in group A 
embryos exposed to 2 mM valproate (Figure 5.1). In groups B and C, the embryos exposed to 40 
mM or lower have heart beat, however, dose-dependent reductions of the rates of heart beat in 
both groups were noticed (Figure 5.2-5.3). In group A, a total of 24 embryos were exposed to 5 
mM VPA, and examined on three consecutive days (6-8 dpf); only 2, 1, and 1 of 24 embryos had 
heart beats on 6, 7, and 8 dpf respectively. Additionally, the mean rates of the heart beat on these 
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three consecutive days were 6.58, 5.21, and 5.40 beats per minute. These heart rates are much 
lower than those of groups B and C, which are above 90 beats per minute (Figure 5.1-5.3). It was 
shown that VPA has a more deleterious effect on the early developmental stage (group A) of 
Japanese rice fish embryos. In group B, no embryo exposed to 40 mM VPA had heart beats on 6 
dpf, while 8.33% and 16.67% of group B embryos had heart beats on 7 dpf and 8 dpf 
respectively (Figure 5.2). The heartbeat normally starts at 44 hrs post fertilization (Iwamatsu 
stage 24), and the embryos in group B (1-3 dpf) started VPA treatment before the onset of the 
heartbeats. When the embryos of group B were treated with 40 mM VPA, the heart beat of some 
embryos, which should initiate around 2 dpf, were delayed due to VPA toxicity and gradually 
started after 6 dpf. These data demonstrate that VPA can delay the onset of heart beat. All the 
embryos of group C started the VPA treatment after their heartbeats have already initiated. The 
percentage of embryos with heartbeats in group C, if they were exposed to 40 mM VPA, 
decreased from 66.67% on 6 dpf, to 54.17% on 7 dpf and finally down to 50% on 8 dpf (Figure 
5.3). This demonstrates that high dose VPA can inhibit heartbeat after it has already initiated 
(Figure 5.3). In group A, no embryo survived if the exposure concentration of VPA was above 
5mM, and the heart rates of group B embryos were reduced more sharply by increasing the 
concentration of VPA comparing with those of group C embryos (Figure 5.1-5.3). To sum up, in 
groups A, B and C, the VPA-induced teratogenic effects on the onset and rates of heart beats are 
 40 
 
dose/developmental stage-dependent.   
3.3.1.2 VPA effects on thrombus formation 
On 6 day post fertilization, a significant number of thrombi were noticed in the embryos 
that survived valproate exposure (group A 5 mM, group B 5 mM and 10 mM, and group C 20 
mM, 40mM and 80 mM subgroups). Moreover, thrombi were seen only in those embryos that 
had developed heartbeats. When valproate treatment prevented initiation of heartbeat, no thrombi 
were seen. Embryos of Japanese rice fish normally start heartbeats first (44 hpf, Iwamatsu 
developmental stage map) and then blood circulation (50 hpf, Iwamatsu developmental stage 
map). Embryos of groups A and B were exposed to VPA before the initiation of heartbeat and 
blood circulation. Additionally, some embryos in group A (0-2 dpf) and group B (1-3 dpf) 
exposed to higher concentration of VPA (5 mM or higher) possessed thrombi even though they 
lacked blood circulation (Figure 6.1). No matter in which group, the higher the concentration of 
VPA, the more thrombi appeared. In addition, with the elevated concentrations of VPA, more 
thrombi were shown in the embryos without circulation on 6 dpf. Some of these embryos have 
not developed onset of circulation, while the circulatory system of others was inhibited after its 
onset. An interesting phenomenon is group B (1-3 dpf) embryos treated with 20 mM valproic 
acid exhibited no thrombus development on 6 dpf. It was suggested that the thrombi were seen 
only in those embryos that have the ability to develop blood vessels. If valproate treatment (high 
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concentration of VPA) is able to stop blood vessel formation, no thrombus would have been seen. 
Embryos in group C (4-6 dpf) were exposed to VPA after they had already started heartbeat and 
blood circulation. Therefore, the thrombus formation in group C was probably due to the 
detrimental effects of VPA toxicity which lead to injury of the endothelial cells of blood vessels 
(Figure 6.1). Embryos in the late development stage (4-6 dpf) were more resistant to the 
VPA-induced teratogenesis, and therefore some embryos (4-6 dpf) treated with 20mM, 40 mM or 
80 mM VPA were alive and presented thrombus on 6 dpf. This is different from embryos in the 
early development stage (0-2 dpf and 1-3 dpf). The onset of heartbeat is a crucial factor in the 
thrombus formation. Onset of blood circulation also plays an important role in thrombus 
formation. Thrombus formation is both dose and developmental-stage dependent.  
3.3.1.3 VPA effects on circulation 
The onset of embryonic blood circulation was also found to be dose and developmental 
stage-specific (Figure 6.2). It was observed that almost all the embryos that were able to hatch 
successfully had well developed circulatory vessels and the blood circulated in the body and yolk 
through these vessels. However, of those embryos that were unable to hatch, the majority of 
them had either no blood vessels or difficulties in obtaining blood circulation. When observed on 
6 dpf, group A embryos exposed to 2 mM, and most of group B embryos exposed to 2 and 5 
mM, were able to circulate blood through vessels. Less than 5% of group A embryos exposed to 
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5 mM VPA, or group B embryos exposed to 10 mM VPA had vessel circulation on 6 dpf (Figure 
6.2). The majority of group C embryos that were treated with 2, 5, 10 mM concentration of VPA 
had blood circulation on 6 dpf. However, as development proceeded in this group, a 
dose-dependent loss (5, 10 mM VPA ) of vessel circulation was noticed. With increasing 
concentrations of VPA, the incidence of thrombus was elevated and the condition of thrombus 
became more severe in all groups. In general, circulation could be prevented by valproate, and 
finally, this could prevent embryos from hatching. Embryos exposed to 10 mM VPA or higher in 
group A, 20 mM VPA or higher in group B were unable to start blood circulation. In group C, 
46.875% of embryos exposed to 20 mM VPA exhibited blood circulation. This indicates that the 
late developmental stage is more resistant to VPA-induced teratogenesis. When compared to 
controls, the incidence of blood circulation of 20 mM VPA-treated embryos in group C was 
decreased significantly (53.125% ) on 6 dpf (Figure 6.2). 
3.3.2 VPA effects on the hatchlings 
The hatched embryos with 2 mM VPA embryonic exposure prenatally seldom exhibited 
bent tails, but they might manifest yolk edema. However, under the embryonic treatment of 4mM 
VPA, the hatched embryos are probable to present bent tails, diminished body length and yolk 
edema (Figure 7).  
3.3.3 VPA effects on the craniofacial cartilages 
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The craniofacial cartilages were examined within 24 hrs of hatching after staining with 
Alcian blue (group E: early developmental stage without circulation (0-2 dpf treatment); group L: 
late developmental stage with circulation (4-6 dpf treatment)) (Table 5). The neurocranium of 
Japanese rice fish embryos starts chondrification, which is to develop into cartilage or become 
cartilaginous in ovo on 5 dpf (Iwamatsu stage 33). This completes prior to or after hatching until 
hatchlings reach Iwamatsu stage 40. A typical Japanese rice fish embryo immediately after 
hatching possesses a chondrocranium which includes auditory and nasal capsules, a 
well-developed neurocranium and splanchnocranium and a minimal amount of chondral 
braincase elements (Figure 8-9). The detailed values for each of the treatment groups are listed in 
table 4. Six cartilages, POC, auditory capsule, PBC in the neurocranium and PT, HYS and HYO 
in the splanchnocranium were not considered for measurement due to irregular (non-linear) 
shapes. 
3.3.3.1 Neurocranial Cartilages: 
3.3.3.1.1 Neurocranium 
It was observed that, in general, compared to controls the linear length of the 
neurocranium of hatchings in groups E and L treated with 2 mM valproate were significantly 
reduced (Figure 10 & Table 7). This indicates that VPA exerted a detrimental influence over the 
entire neurocranium. 
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3.3.3.1.2 Trabeculae (TC) 
Compared to controls, TC was significantly reduced 8.08% in group E (0-2 dpf) 
hatchlings exposed to 2 mM valproate prenatally but not in group L hatchlings (Figure 10 & 
Table 7). This indicates that early developmental stages are more sensitive to the deleterious 
effects resulting from VPA toxicity. 
3.3.3.1.3 Epiphyseal Bar (EB) 
The linear lengths of the EB in hatchlings (group E, 0-2 dpf treatment) treated with 2 mM 
VPA were significantly reduced 8.17% compared with controls. EB from group L hatchlings (4-6 
dpf) with 2 mM VPA treatment grow much larger than those from group E (1-3 dpf) treated with 
the same concentration of VPA. This indicates that VPA toxic effects are developmental-stage 
specific and that VPA toxic effects are more pronounced in the early developmental stage (Figure 
10 & Table 7).  
3.3.3.1.4 Anterior Orbital Cartilage (AOC) 
AOC displayed significant reduction (10.19%) in linear length relative to controls only in 
group E hatchlings (0-2 dpf) treated with 2 mM VPA. The development of AOC in group L (4-6 
dpf) hatchlings with 2 mM VPA exposure was not significantly affected. Compared with group E 
with the same concentration of VPA treatment, AOC in group L treated with 2 mM VPA grows 
much longer (15.28%) (Figure 11 & Table 7). These data indicate that toxicity caused by VPA is 
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predominant in the early developmental stage. 
3.3.3.1.5 Anterior Basicranial Commissure (ABC) 
ABC remained unaltered in hatchlings of 2 mM VPA-treated groups E (0-2 dpf) and L 
(4-6 dpf) when compared with controls. It was determined that ABC was significantly longer in 
group L hatchlings with 2 mM VPA treatment than it was in group E with the same treatment 
(Figure 11 & Table 7). This may be due to the fact that early developmental stage suffers more 
severely from VPA toxicity.  
3.3.3.1.6 Basilar Plate (BP) 
The linear length of BP in group E hatchlings (0-2 dpf) treated with 2 mM Valproate was 
reduced significantly (4.27%) when compared with controls. BP of group E hatchlings with 2 
mM VPA treatment prenatally were significantly smaller (6.17%) compared with those 
correspondingly hatchlings in group L (4-6 dpf) (Figure 11 & Table 7). These data suggest that 
the teratogenic effects from VPA toxicity were more remarkable in the early developmental 
stage. 
3.3.3.1.7 Polar Cartilage (PC) 
It was shown that 2 mM VPA only decreased PC in group L hatchlings significantly 
(24.47%) when exposed embryonically (Figure 11 & Table 7). VPA manifested its detrimental 
impacts on PC in the late developmental stage. 
 46 
 
3.3.3.2 Splanchnocranium 
3.3.3.2.1 Meckel's Cartilage (MC) 
MC showed no reduction in 2 mM VPA-treated hatchlings of groups E and L compared 
with controls (Figure 12 & Table 7). 
3.3.3.2.2 Quadrate (QU) 
Compared to controls, the hatchlings with 2 mM VPA exposure exhibit significantly 
shorter QU in groups E and L respectively. QU of the hatchlings with 2 mM VPA exposure 
prenatally in group E demonstrated significant reduction (6.33%) in length compared with those 
treated with the same concentration of VPA in group L (Figure 12 & Table 7). It is observed that 
the early developmental stage is most subject to the damage derived from VPA toxicity. 
3.3.3.2.3 Basihyal (BH) 
Compared to controls, there were no alterations in the linear lengths of BH of the 
hatchlings in groups E and L respectively (Figure 12 & Table 7). 
3.3.3.2.4 Ceratohyal (CH) 
It was recorded that the linear lengths of CH of the hatchlings in both groups E and L 
treated with 2 mM VPA were decreased significantly (7.41% for group E and 8.24% for group L) 
compared to controls (Figure 12 & Table 7).  
3.3.3.2.5 Basibranchial 1-3 (BB 1-3) 
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BB 1-3 revealed significant reduction in the linear lengths from the hatchlings exposed to 
2 mM VPA embryonically in groups E and L, compared with controls. BB 1-3 in group E with 2 
mM prenatal VPA exposure were significantly shorter (10.97%) than those in group L (Figure 13 
& Table 7). It was indicated that the early developmental stage (0-2 dpf)  possesses less 
resistant capability to VPA toxic effects. 
3.3.3.2.6 Basibranchial 4 (BB 4) 
VPA produced no modification of BB 4 in any treatment groups (Figure 13 & Table 7). 
3.3.3.2.7 Ceratobranchial 1 (CBR 1) 
It was shown that CBR 1 of the hatchlings treated with 2 mM VPA prenatally was 
reduced in length significantly only in group L when compared with controls (Figure 13 & Table 
7). This indicates that CBR1 at the late developmental stage is more sensitive to VPA toxicity.  
3.3.3.2.8 Ceratobranchial 2 (CBR 2) 
CBR 2 displayed significant reduction in linear length only in the hatchlings of group L 
treated with 2 mM VPA, when compared with controls (Figure 13 & Table 7). This indicates that 
CBR2 at the late developmental stage is most subject to the toxic effects of VPA. 
3.3.3.2.9 Ceratobranchial 3 (CBR 3) 
Compared to controls, the linear length of CBR 3 in the hatchlings decreased 
significantly (11.40%) only in 2 mM VPA-treated group L. (Figure 14 & Table 7). This indicates 
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that the late development of CBR3 is more resistant to VPA-induced teratogenesis. 
3.3.3.2.10 Ceratobranchial 4 (CBR 4) 
Compared to controls, the linear length of CBR 4 was decreased significantly (17.46%) 
only in the hatchlings of group L embryonically treated with 2 mM VPA. The linear length of 
CBR 4 in the hatchlings of group L treated with 2mM VPA displayed significant reduction when 
compared with those in group E (Figure 14 & Table 7). It is suggested that VPA exerts toxic 
effects on CBR 4 at the late developmental stage.  
3.3.3.2.11 Ceratobranchial 5 (CBR 5) 
It was found that, compared to controls, hatchlings displayed significantly reduced linear 
length of CBR 5 (25.27%) only in the hatchlings of group L that were embryonically exposed to 
2 mM VPA (Figure 14 & Table 7). This indicates VPA-induced teratogenic effects on CBR 5 are 
more apparent at the late developmental stage.  
3.4 Biochemical analysis of Japanese rice fish embryos exposed prenatally and 
developmentally to VPA. 
To find a molecular characteristic related to VPA-induced teratogenesis in 
valproate-treated Japanese rice fish, we have analyzed mRNA expression patterns for nine genes 
that are related to oxidative stress (catalase, glutathione-s-transferase, glutathione reductase), 
neurogenesis (iro3, nlgn3b, wnt1, shh, otx2) and cell division (shh, cyclin a2). All of these genes 
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have been reported to be expressed in Japanese rice fish embryos during morphogenesis. In this 
experiment, Japanese rice fish embryos were exposed to two concentrations of valproate for 48 
hrs in three developmental stages (group A: 0-2 dpf; group B: 1-3 dpf; group C: 4-6 dpf). Group 
A embryos were exposed to 1 and 2 mM, and groups B and C embryos were exposed to 2 and 5 
mM of valproate. The treatment continued for 48 hrs with a one time change of the media at 24 
hrs. The embryos in each group were sacrified for mRNA analysis immediately after treatment. 
The primers used for rRT-PCR are presented in Table 5. 
3.4.1 Oxidative Stress 
VPA did not alter the catalase, gst, or gr mRNA expression levels indicating that VPA 
toxicity probably was not the result of oxidative stress. 
3.4.1.1 Catalase 
The data obtained by rRT-PCR showed that the embryos treated with different 
concentrations of VPA were able to maintain equal levels of catalase mRNAs within groups A, B 
and C just after VPA treatment for 48 hrs (Figure 15.1). Therefore, VPA did not affect catalase 
mRNA levels. 
3.4.1.2 Glutathione-S-Transferase (gst) 
Embryos in groups A, B and C did not show significant reduction or increase in gst 
mRNA expression levels when compared to their corresponding controls. In conclusion, VPA did 
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not have an impact on gst mRNA expression pattern. Glutathione-S-transferase mRNA 
expression level significantly increased in controls on 6 dpf in contrast to those on 2 dpf. This 
suggested that gst mRNA is expressed constitutively and upregulated as the development of 
embryos go on (Figure 15.2).  
3.4.1.3. Glutathione Reductase (gr) 
The gr mRNA contents remained unaltered after valproate exposure in groups A, B and C 
(Figure 15.3). 
3.4.2 Neurogenesis 
3.4.2.1 Neuroligin 3b (nlgn 3b) 
The neuroligin 3b mRNA expression pattern was altered in a dose and developmental 
stage-specific manner. When compared to controls, embryos of group B with 5 mM VPA 
exposure showed statistically significant reductions (84.04%) in nlgn 3b mRNA levels. It is 
indicated that the nlgn mRNA expression levels tend to be reduced in VPA-treated embryos, and 
the extent of reduction elevates with increasing concentration of VPA. It is believed that a larger 
number (n) of experiments would make this result significant. The nlgn 3b mRNA in controls 
manifested an elevated expression pattern in groups B and C when compared with those in group 
A, suggesting that neuroligin 3b mRNA is expressed constitutively and upregulated as the 
development of embryos continues (Figure 16.1). 
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3.4.2.2 Orthodenticle Homeobox 2 (Otx2) 
The otx2 mRNA expression pattern was modified in a dose and developmental 
stage-specific method. Compared with controls, the expression levels of otx2 mRNA were only 
reduced by valproic acid in group B embryos treated with 5 mM VPA. Compared with controls 
in group A, otx2 mRNA expression levels were upregulated in controls of groups B and C (on 3 
dpf and 6 dpf ) (Figure 16.2). This suggested that otx2 mRNA was expressed constitutively and 
its level was upregulated as the development of the embryos progressed.  
3.4.2.3 Wingless-type Mouse Mammary Tumor Virus Integration Site Family, Member 1 
(Wnt1) 
The wnt1 mRNA expression pattern was altered in a dose and developmental 
stage-specific manner. Wnt1 mRNA expression level was only reduced in embryos of group B 
treated with 5 mM valproic acid. Wnt1 mRNA content of controls on 6 dpf was less than the 
content on 3 dpf (P<0.0001) (Figure 16.3). It is indicated that wnt1 is constitutively expressed 
and its expression level was changed by the treatment of valproic acid during 1-3 dpf for 48 hrs.  
3.4.2.4 Iroquois 3 (iro3) 
The data obtained by rRT-PCR showed that the embryos from groups A, B and C with 
VPA treatment maintained similar amounts of iro3 mRNA content when compared with controls 
(Figure 16.4). Thus, iro3 mRNA expression levels remained unaltered after valproate exposure. 
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It is indicated that the toxic effects of valproic acid were not derived from modification of iro3 
mRNA expression pattern. 
3.4.3 Cell Division 
3.4.3.1 Sonic Hedgehog (shh) 
The shh mRNA expression was modified in a dose and developmental stage-specific 
manner. Only in group A were shh mRNA expression levels reduced 46.35% in embryos exposed 
to 2 mM VPA (Figure 17.1). This suggests that the shh mRNA expression pattern was altered by 
valproic acid in the early developmental stage of embryos, which is the cell division phase 
(group A: 0-2 dpf). Therefore, VPA probably manifested its teratogenesis by inhibiting cell 
division during early development of embryos.  
3.4.3.2 Cyclin A2 (ccna2) 
The mRNA expression of ccna2 was inhibited by valproic acid treatment significantly at 
2 mM concentration in group A (46.33%) and 5 mM in group C (19.37%), when compared with 
the corresponding controls. Since cyclin A2 is the gene that controls the progression of cell cycle 
and 0-2 dpf is the critical phase for cell division, the result suggests that VPA may exert its 
toxicity by reducing cell division (Figure 17.2).
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Table 4: Treatment groups classification of Japanese rice fish embryos used for 
determination of the LC50s of VPA, the effects of VPA on the cardiovascular development 
and the mRNA expression levels of the related genes     
 
 
 
 
 
 
 
 
 
 
 
 
Groups VPA treatment (hour 
post fertilization) 
Developmental stages at the beginning 
of VPA treatment ( Iwamatsu, 2004) 
Observations after 
VPA removal (h) 
A 0-48 4-10 ~96 
B 24-72 17-20 ~72 
C 96-144 31-32 ~1 
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Table 5: Treatment groups classifications of Japanese rice fish embryos used for 
measurement of craniofacial cartilages 
 
 
 
 
 
 
 
 
 
 
 
Groups VPA treatment (hour 
post fertilization) 
Developmental stages at the beginning of 
VPA treatment ( Iwamatsu, 2004) 
Observations after 
VPA removal (h) 
E 0-48 4-10 ~96 
L 96-144 31-32 ~1 
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Figure 3: Valproate-mediated mortality in Japanese rice fish embryos. Fertilized eggs of 
Japanese rice fish within 4 hpf (A), 24 hpf (B) and 96 hpf (C) were exposed to valproate (0-80 
mM) for 48 h and then transferred to clean hatching solution. The effect on mortality was 
recorded on 14 dpf. The experiment was repeated 3 times and each treatment group consisted of 
8 embryos. The calculated LC50 values are 1.68 ± 1.55 mM for group A (r2=0.83), 26.45 ± 1.64 
mM for group B (r2=0.88) and 20.37 ± 3.30 mM for group C (r2=0.55). LC50s were calculated 
from transformed data (log valproate concentration) using a nonlinear regression (curve-fit) 
program (GraphPad Prism). Each data point represents the mean mortality precentage ± SEM 
(n=3). These data indicate that group A embryos were more sensitive to valproate than groups B 
and C. 
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Table 6: The LC50 values of Japanese rice fish embryos exposed to VPA at three different 
developmental stages 
 
Group LC50 
group A 1.68 ± 1.55 mM 
group B 26.45 ± 1.64 mM 
group C 20.37 ± 3.3 mM 
 57 
 
Hatching efficiency
Co
n
tr
o
l
 
2 
m
M
-
A
5 
m
M
-
A
2 
m
M
-
B
5 
m
M
-
B
10
 
m
M
-
B
2 
m
M
-
C
5 
m
M
-
 
C
10
 
m
M
-
C
0
50
100
150
*
*
*
* *
Em
br
yo
s 
Ha
tc
h
(%
)
 
 
Figure 4: Hatching efficiency of Japanese rice fish embryos developmentally exposed to 
valproate. Embryos at specific developmental stages (A, B, and C) were exposed to different 
concentrations of valproate (0-80 mM) for 48h. Then they were transferred to clean hatching 
solution.  Parallel groups with no valproate served as controls. For group details see Table 4. 
Hatching was recorded from 7+ dpf. Each group consists of eight embryos and the experiment 
was repeated 3 times. Each bar is the mean ± SEM of 3 independent experiments. Bar head 
with asterisks (*) indicate that the data were significantly different (P<0.05) from the controls 
(no valproate). 
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Figure 5: Heart rates of Japanese rich fish embryos exposed to Valproate during 
development. Fertilized embryos were exposed to valproate (0-80 mM) for 48 h in groups A, B 
and C and then transferred to clean hatching solution. Parallel groups with no valproate served as 
controls. For group details see Table 4. Heart rates were examined on 6, 7, and 8 dpf. Each group 
contained 8 embryos per treatment. Each bar is the mean ± SEM of three independent treatment 
repetitions. Bar head with pound symbol (#) indicates that the data are significantly different 
(P<0.05) from the corresponding controls (no valproate). Figure 5.1: heart rates of group A; 
figure 5.2: heart rates of group B; figure 5.3: heart rates of group C. The effects of valproate on 
heart rates were dose- and developmental stage-specific. 
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Figure 6: The occurrence of thrombi and blood circulation observed on 6 dpf in embryos 
after exposure to valproate at three different developmental stages (groups A, B, and C). 
Fertilized embryos were exposed to valproate (0-80 mM) for 48 h in groups A, B and C and 
then transferred to clean hatching solution. Parallel groups with no valproate served as controls. 
For group details see Table 4. The incidences of thrombi and vessel circulation onset were 
examined on 6 dpf. Each group contained 8 embryos per treatment. Each bar is the mean ± 
SEM of three independent treatment repetitions. Bar head with asterisks (*) indicate that the 
data are significantly different (P<0.05) from the corresponding controls (no valproate). Figure 
6.1= Incidence of thrombi in each group observed on 6 dpf. Figure 6.2= Incidence of vessel 
circulation onset in each group observed on 6 dpf. The effects of valproate on occurrence of 
thrombi and vessel circulation were dose- and developmental stage-specific.
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(A)  Control                                              (B) 2mM –Group C                                           (C) 4mM –Group C (Spine cord is curved.)    
A   B C 
 
 
 
Figure 7: Representative photomicrographs displaying teratogenic effects of valproate in 
hatched Japanese rice fish. Embryos (4 dpf) were exposed to 2 mM and 4 mM VPA for 48 h 
(4-6 dpf) and then maintained in clean hatching solution without VPA until hatching. The 
photographs were taken with an Olympus BX 40F-3 microscope at fixed magnification (40X). 
Figure 7.1: control; 7.2: embryos exposed to 2 mM VPA; 7.3: embryos exposed to 4 mM 
valproate. Arrow (   ) represents the area where the yolk edema was seen. In valproate-treated 
hatchlings, yolk edema (7.2) and bent tail (7.3) are seen.
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Table 7: Effect of valproate on the length of neurocranial and splanchnocranial cartilages 
(um) of Japanese rice fish hatchlings 
Locations Cartilag
e Name 
Group E 
Control 
Group E 
2 mM VPA 
Group L 
Control 
Group L 
2mM VPA 
Neurocranium NRC 920±9.9 883±10.1* 945±10.0 910±9.8* 
TC 198±4.6 182±2.5* 200±3.9 186±8.7 
EB 306±4.7 281±4.5* 319±4.3 311±4.9 
AOC 216±5.1 194±7.2* 229±4.3 229±8.2 
ABC 435±6.6 424±5.6 453±7.1 444±5.3 
BP 445±6.1 426±7.3* 457±11.3 454±5.6 
PC 56±2.4 49±2.7 61.7±2.9 46.6±3.8* 
Splanchnocranium MC 118±4.3 116±2.0 125±3.0 118±4.0 
QU 335±4.8 311±7.2* 346±4.3 332±6.0* 
BH 158±8.6 167±8.7 171±5.8 161±7.5 
CH 270±5.8 250±5.9* 279±4.1 256±4.7* 
BB 1-3 339±7.3 284±7.6* 360±5.7 319±8.7* 
BB 4 43±1.8 41±2.3 46±2.6 47±3.0 
 62 
 
 
Japanese rice fish embryos were exposed to 2 mM VPA with or without circulation for 48 
hrs at two different developmental stages (group L: treatment during 4-6 dpf; group E: treatment 
during 0-2 dpf). After 48 hrs treatment, they were transferred to clean hatching solution to allow 
the embryos to hatch. For group details see Table 5. Groups E and L hatchlings within~24 hrs 
after hatching were preserved in 4% PFA and used for cartilage staining with alcian blue. The 
cartilage length was measured with an Olympus BX 40F-3 microscope with image analysis 
software. NRC= Neurocranium; EP= Ethmoid plate; TC= Trabecular cartilages; EB= Epiphyseal 
bar; AOC = Anterior orbital cartilages; ABC= Anterior basicranial commisure; BP = Basilar plate; 
PC = Polar cartilages; MC = Meckel’s cartilage (lower jaw); QU = quadrate; BH= Basihyal; CH 
= Ceratohyal; BB1-3 = Basibranchials 1-3; BB4 = Basibranchial 4; CBR 1-5 = ceratobranchials 
1-5; GWC= Groups with circulation; GWOC= Groups without circulation. The nomenclature of 
the cartilages used in this communication was obtained from Langille and Hall (1987). The 
results are expressed as mean ± SEM. The data are analyzed by unpaired t test. Asterisks (*) 
indicate that the value is significantly different from corresponding controls (no valproate). The 
deleterious impacts caused by VPA on splanchnocranial cartilages are developmental-stage 
dependent.
CBR 1 211±6.2 199±3.9 227±6.0 189±6.1* 
CBR 2 212±5.8 200±3.8 227±5.0 199±4.0* 
CBR 3 213±6.5 208±3.7 228±4.7 202±4.4* 
CBR 4 243±5.9 230±4.4 252±6.6 208±7.0* 
CBR 5 169±5.9 163±5.3 186±7.4 139±13.8* 
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Figure 8: Representative photomicrographs of neurocranial cartilages of Japanese rice fish 
hatchlings (14 dpf). The hatchlings (14 dpf) were stained with alcian blue and pictures (100X) 
were taken with an Olympus BX 40F-3 microscope. The picture presented above displays the 
locations of the different cartilages in the neurocranium (dorsal view) of Japanese rice fish 
hatchlings.
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Figure 9: Representative photomicrographs of splanchnocranial cartilages of Japanese rice 
fish hatchlings (14 dpf). The hatchlings (14 dpf) were stained with alcian blue and pictures 
(100X) were taken with an Olympus BX 40F-3 microscope. The picture presented above 
displays the locations of the different cartilages in the splanchnocranium (dorsal view) of 
Japanese rice fish hatchling 
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Figure 10: Effects of valproate on the development of neurocranial cartilages (neurocranium, 
trabeculae and epiphyseal bar) of Japanese rice fish embryos. Embryos with (group L: 4-6 dpf 
treatment) or without (group E: 0-2 dpf treatment) circulation were exposed to 2 mM VPA for 48 hrs, with 
a one time change of medium at the same concentration of VPA at 24 hr. After 48 hrs treatment, the 
embryos were transferred to clean hatching solution, and then maintained with a 50% static renewal of 
medium per day until they hatched. For group details see Table 5. The hatchlings were preserved in 4% 
PFA within~24hrs after hatching and were stained with 0.1% Alcian blue. The cartilage length was 
measured with an Olympus BX 40F-3 microscope with image analysis software. The results are 
expressed as mean ± SEM. The data were analyzed by unpaired t test. Asterisks (*) indicate that the 
values are significantly different (P<0.05) from the corresponding controls and pound symbol (#) 
indicates the difference (P<0.05) of the data with group E at 2 mM VPA treatment. The deleterious 
impacts caused by VPA on neurocranial cartilages are developmental-stage dependent. 
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Figure 11: Effects of valproate on the development of neurocranial cartilages (arterior orbital 
cartilage, anterior basicranial commissure, basilar plate and polar cartilage) of Japanese rice fish 
embryos. Embryos with (group L: 4-6 dpf treatment) or without (group E: 0-2 dpf treatment) circulation 
were exposed to 2 mM VPA for 48 hrs, with a one time change of medium at the same concentration of 
VPA at 24 hr. After 48 hrs treatment, the embryos were transferred to clean hatching solution, and then 
maintained with a 50% static renewal of medium per day until they hatched. For group details see Table 5. 
The hatchlings were preserved in 4% PFA within ~24hrs after hatching and were stained with 0.1% 
Alcian blue. The cartilage length was measured with an Olympus BX 40F-3 microscope with image 
analysis software. The results are expressed as mean ± SEM. The data were analyzed by unpaired t test. 
Asterisks (*) indicate that the values are significantly different (P<0.05) from the corresponding controls 
and pound symbol (#) indicates the difference (P<0.05) of the data with group E at 2 mM VPA treatment. 
The deleterious impacts caused by VPA on neurocranial cartilages are developmental-stage dependent 
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Figure 12: Effects of valproate on the development of splanchnocranial cartilages (Meckel’s 
cartilage, quadrate, basihyal and ceratohyal) of Japanese rice fish embryos. Embryos with (group L: 
4-6 dpf treatment) or without (group E: 0-2 dpf treatment) circulation were exposed to 2 mM VPA for 48 
hrs, with a one time change of medium at the same concentration of VPA at 24 hr. After 48 hrs treatment, 
the embryos were transferred to clean hatching solution, and then maintained with a 50% static renewal of 
medium per day until they hatched. For group details see Table 5. The hatchlings were preserved in 4% 
PFA within ~24hrs after hatching and were stained with 0.1% Alcian blue. The cartilage length was 
measured with an Olympus BX 40F-3 microscope with image analysis software. The results are 
expressed as mean ± SEM. The data were analyzed by unpaired t test. Asterisks (*) indicate that the 
values are significantly different (P<0.05) from the corresponding controls and pound symbol (#) 
indicates the difference (P<0.05) of the data with group E at 2 mM VPA treatment. The deleterious 
impacts caused by VPA on splanchnocranial cartilages are developmental-stage dependent. 
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Figure 13: Effects of valproate on the development of splanchnocranial cartilages (basibranchials 
1-3, basibranchial 4, ceratobranchials 1-2) of Japanese rice fish embryos. Embryos with (group L: 
4-6 dpf treatment) or without (group E: 0-2 dpf treatment) circulation were exposed to 2 mM VPA for 48 
hrs, with a one time change of medium at the same concentration of VPA at 24 hr. After 48 hrs treatment, 
the embryos were transferred to clean hatching solution, and then maintained with a 50% static renewal of 
medium per day until they hatched. For group details see Table 5. The hatchlings were preserved in 4% 
PFA within~24hrs after hatching and were stained with 0.1% Alcian blue. The cartilage length was 
measured with an Olympus BX 40F-3 microscope with image analysis software. The results are 
expressed as mean ± SEM. The data were analyzed by unpaired t test. Asterisks (*) indicate that the 
values are significantly different (P<0.05) from the corresponding controls and pound symbol (#) 
indicates the difference (P<0.05) of the data with group E at 2 mM VPA treatment.. The deleterious 
impacts caused by VPA on splanchnocranial cartilages are developmental-stage dependent. 
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Figure 14: Effects of valproate on the development of splanchnocranial cartilages (ceratobranchials 
3-5) of Japanese rice fish embryos. Embryos with (group L: 4-6 dpf treatment) or without (group E: 0-2 
dpf treatment) circulation were exposed to 2 mM VPA for 48 hrs, with a one time change of medium at 
the same concentration of VPA at 24 hr. After 48 hrs treatment, the embryos were transferred to clean 
hatching solution, and then maintained with a 50% static renewal of medium per day until they hatched. 
For group details see Table 5. The hatchlings were preserved in 4% PFA within~24hrs after hatching and 
were stained with 0.1% Alcian blue. The cartilage length was measured with an Olympus BX 40F-3 
microscope with image analysis software. The results are expressed as mean ± SEM. The data were 
analyzed by unpaired t test. Asterisks (*) indicate that the values are significantly different (P<0.05) from 
the corresponding controls and pound symbol (#) indicates the difference (P<0.05) of the data with group 
E at 2 mM VPA treatment. The deleterious impacts caused by VPA on splanchnocranial cartilages are 
developmental-stage dependent.  
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Table 8: List of primers used in semi-quantitative RT-PCR (rRT-PCR) amplification of the 
mRNAs of Japanese rice fish embryo.
mRNA Sense (5-3) Antisense 
(5-3) 
Product 
(bp) 
GenBank 
accession/ 
Ensembl number 
β-actin cctgaccctgaagtat
ccca 
agcgacaagatgag
ctggtt 
542 ENSORLT00000
017152 
catalase gcggtacaacagcgc
agatgaag 
ggatggacggccttc
aagttc 
171 ENSORLT00000
002176 
Glutathione reductase 
(gr) 
ggactactcctgcattc
ccacag 
cattgactcttcctgc
gtgtgatg 
165 ENSORLT00000
000771 
Glutathione-S-transfera
se (gst) 
gaacctgcagggcta
caacc 
ggccctcaaacatgc
gttgg 
241 GenBankX95200 
Neuroligin 3b (nlgn3b) gatgaggtgccttatgt
gtttg 
ccactttggtggcac
ggtagtg 
292 NM_001201508 
Iroquois homeobox 
protein iro3 (iro3) 
ccagacccaaaaatg
ccacc 
ccttgtaaatcctcat
agccg 
221 AB098317 
Wingless-related 
MMTV integration site 
1 (wnt1) 
gtgggagatttcctca
aggac 
cagcaccagtggaa
agtgcag 
338 AJ243208 
Sonic hedgehog (shh) gatgaggagaacacc
ggagcc 
cttccaccgccagtct
ggac 
241 AB007129 
Orthodenticle 
homeobox2 (otx2) 
ggcctgagcttaacta
cctc 
ggactcgggaagatt
gattgattttc 
201 AJ000939 
CyclinA2 (ccna2) gctacatgaagaagc
agcctg 
gactttgagcaccag
atgctc 
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Figure 15: Effects of valproate on catalase, gst and gr mRNA expression in Japanese rice 
fish at three different developmental stages. Total RNA was prepared from 6-8 pooled 
embryos after valproate treatment at 2 dpf (group A), 3 dpf (group B) and 6 dpf (group C). This 
was reverse transcribed and analyzed by rRT-PCR using β-actin primers as internal control. For 
group details see Table 4. The results were expressed as the ratio of relative band intensity of the 
target gene to the band intensity of the β-actin gene. We took the log of the ratios, and these 
values were used for one way ANOVA followed by Tukey’s post-hoc multiple comparison test; 
p<0.05 was considered as significant. Each data point is the mean ± SEM of 4 separate 
experiments. Bar heads with an asterisk (*) indicate that the value is significantly different from 
the corresponding control (no valproate). Figure 15.1: catalase; Figure 15.2: gst; Figure 15.3: gr. 
The data indicate that VPA teratogenesis may not be derived from oxidative stress. 
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Figure 16: Effects of valproate on nlgn3b, otx2, wnt1 and iro3 mRNA expression in 
Japanese rice fish at three different developmental stages. Total RNA was prepared from 6-8 
pooled embryos after valproate treatment at 2 dpf (group A), 3 dpf (group B) and 6 dpf (group C). 
This was reverse transcribed and analyzed by rRT-PCR using β-actin primers as internal control. 
For group details see Table 4. The results were expressed as the ratio of relative band intensity of 
the target gene to the band intensity of the β-actin gene. We took the log of the ratios, and these 
values were used for one way ANOVA followed by Tukey’s post-hoc multiple comparison test; 
p<0.05 was considered as significant. Each data point is the mean ± SEM of 4 separate 
experiments. Bar heads with an asterisk (*) indicate that the value is significantly different from 
the corresponding control (no valproate).  Figure 16.1: nlgn3b; Figure 16.2: otx2; Figure 16.3: 
wnt1; Figure 16.4: iro3. 
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Figure 17: Effects of valproate on shh and ccna2 mRNA expression in Japanese rice fish at 
three different developmental stages. Total RNA was prepared from 6-8 pooled embryos after 
valproate treatment at 2 dpf (group A), 3 dpf (group B) and 6 dpf (group C). This was reverse 
transcribed and analyzed by rRT-PCR using β-actin primers as internal control. For group details 
see Table 4. The results were expressed as the ratio of relative band intensity of the target gene to 
the band intensity of the β-actin gene. We took the log of the ratios, and used these values for one 
way ANOVA followed by Tukey’s post-hoc multiple comparison test; p<0.05 was considered as 
significant. Each data point is the mean ± SEM of 4 separate experiments. Bar heads with an 
asterisk (*) indicate that the value is significantly different from the corresponding control (no 
valproate). Figure 17.1: shh; Figure 17.2: ccna2. 
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CHAPTER 4  
DISCUSSION 
Valproate is preferred to treat absence seizures, generalized tonic-clonic seizures, 
myoclonic seizures and partial seizures. In addition, it is also very effective for treating bipolar 
disorder and migraine. Epilepsy is a common neurological disorder that affects 0.5-1 % of 
pregnant women (Fairgrieve, 2000; Holmes et al., 2001). Approximately 0.3% of all pregnant 
women are in need of a balanced antiepileptic drug treatment (Morrell, 2002), even though 
these drugs (carbamazepine, valproic acid, phenobarbital, phenytoin, lamotrigine, etc.) are 
known to be teratogens to children born to mothers taking them during pregnancy. These 
epileptic drugs are responsible for a wide spectrum of fetal malformations and severe cognitive 
disorders in the offspring, such as fetal valproate syndrome (FVS) and/or autistic spectrum 
disorders (ASDs). Since valproic acid is very specialized to treat some types of convulsive 
disorders and has relatively less sedative effects, it is widely used worldwide. A significant 
portion of pregnant women with epilepsy take valproate, either as monotherapy or as a part of 
polytherapy (Kini, 2006). The embryonic and fetal damages caused by antiepileptic drugs are 
described into three major categories (Ornoy, 2009): (1) Elevated risks of major congenital     
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anomalies include neural tube defects, cardiovascular, orofacial and digital abnormalities, 
deformities of eye, skin, abdominal wall, brain, respiratory tract and genitourinary systems, etc.; 
(2) A specific syndrome, ‘Fetal Valproate Syndrome’, presented with facial dysmorphic features 
(figure 2), but also involves damages to other organs, such as the neural tube; 
(3)Neurodevelopmental disorders that affect cognitive, social and verbal skills, and lead to 
stereotypic behaviors, such as autism-like symptoms.  
It is evident from the present experimental results that Japanese rice fish embryos 
exposed to valproate during development displayed several measurable phenotypic end points 
analogous with human FVS. These end points were especially apparent in the cardiovasculature, 
neurocranial and splanchnocranial cartilages. Human FVS which is characterized by distinctive 
facial appearance, a cluster of major and minor anomalies (Table 2), and dysfunctions of CNS 
(Kozma, 2001). Our studies were focused on some of the phenotypic features that were altered 
by VPA in the Japanese rice fish, such as cardiovascular and craniofacial abnormalities that 
appear to correlate with the phenotypes observed in human FVS. Our data demonstrate that 
valproate is a teratogen in Japanese rice fish, and the teratogenic effects are specific to the 
developmental stages of the embryos. Usually, the earlier the exposure, the more severe the 
deleterious effects. It is well known that during morphogenesis, each tissue and organ have 
critical phases during which their development may be disrupted by various teratogens. 
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Therefore, to find stage-specific effects, in our model, embryos were exposed to valproate at 
three stages of development (groups A, B and C) (Table 4). Group A embryos were treated with 
VPA during 0-2 dpf, group B embryos during 1-3 dpf, and group C embryos during 4-6 dpf. 0-2 
dpf and 1-3 dpf are critical periods for cell division and neurogenesis respectively. 4-6 dpf is the 
period of time after formation of the cardiovascular system. The calculated LC50 as determined 
on 14 dpf suggests that the embryos, at early stages of development (group A), were more 
sensitive to valproate than those in late stages (groups B and C). A recent study in zebrafish 
embryos by Selderslaghs et al. (2009) determined IC50 after exposing 2-4 hpf embryos to VPA 
continuously for 24, 48, 72, and 144h. In an earlier study in zebrafish, Gurvich et al. (2005) 
reported that valproate concentrations higher than 3 mM were cytotoxic, leading to rapid 
developmental arrest and cell lysis (the valproate exposure period was 5.3- 24 hpf). Although the 
experimental conditions and the developmental stages in which the zebrafish embryos were 
exposed to valproate were different from our studies with Japanese rice fish (Gurvich et al., 2005; 
Selderslaghs et al., 2009), it is evident that Japanese rice fish embryos were relatively more 
resistant to valproate in late stages of development (groups B and C; LC50s are 26.45±1.64 mM 
and 20.37±3.30 mM, respectively, n= 3), compared with zebrafish (LC50 for 48 h exposure is 
2.09 mM; Selderslaghs et al., 2009). In addition, we consider that the culture medium also affects 
the sensitivity of the Japanese rice fish embryos to valproate. We added NaHCO3 (∼2.38 mM) to 
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the hatching solution as it is required for maintaining the pH of the embryo-rearing medium. 
Bicarbonates have been demonstrated to compete with valproate during cellular uptake in 
Dictyostelium, zebrafish and xenopus (Terbach et al., 2011). Therefore, because of the 
competition, we expect that the actual concentration of valproate available to the embryo in 
Japanese rice fish to induce toxicity is significantly lower than that of the calculated LC50 values 
determined during the present experiments. 
The deleterious effects of valproate on cardiovascular development, in our studies, were 
restricted to increased thrombus formation, delayed blood circulation, and lower heart rates 
which were found to be affected significantly and are dose and developmental-stage specific. 
These effects were observed in each VPA treatment group. Embryos treated with higher 
concentrations of VPA displayed more severe effects. In addition, embryos treated with VPA at 
early developmental stages were more sensitive to VPA toxicity. Thrombi were seen only in 
those embryos which were able to develop heart beat. If embryos exposed to VPA before they 
developed blood circulation (groups A and B), some embryos showed thrombus formation on 6 
dpf with heart beating but without onset of blood circulation. This may be due to the reason that 
blood vessels cannot develop normally to allow blood flow under VPA treatment, and thus 
thrombi appear. However, some embryos exposed to high concentration of VPA (20 mM) 
developed heart beat but did not exhibit thrombus formation. This suggests that the detrimental 
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impacts of high dose VPA are more severe than those of low dose VPA, and high dose VPA 
apparently prevents the formation of blood cells. Therefore, no thrombus appeared. When blood 
vessels developed before VPA treatment (C group), the VPA displayed its toxicity by acting 
directly on the blood vessels to cause thrombus formation. Additionally, the initiation of blood 
circulation was delayed in valproate exposed embryos in a dose and developmental-stage 
dependent manner. Moreover, group C embryos, which had established blood circulation prior to 
exposure to valproic acid, did not undergo any significant alterations in blood circulation during 
the 48 hrs of valproate exposure. If these embryos (group C) were then maintained in clean 
hatching solution and allowed to continue developing, thrombi became apparent, vessel 
circulation got slower or stopped, and the embryos were either unable to hatch or died (data not 
shown). The heart rate was determined on 6th, 7th and 8th dpf when there was no valproate in the 
medium.  Our data indicate that the heart rate of the embryos was reduced in a dose and 
developmental-stage specific manner. It was also manifested that VPA can inhibit heart beating 
even if it had already initiated. Several studies have indicated that valproate affects blood vessel 
development by inhibiting angiogenesis (Michaelis et al., 2004). In Jcl :ICR mouse, 
administration of valproic acid to the mother induced fetal cardiovascular abnormalities such as 
ventricular septal defect, endocardial cushion defect, transposition of the great arteries, double 
outlet right ventricle, tricuspid atresia and hypoplastic left heart syndrome(Sonoda et al., 1993). 
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In murine pluripotent embryonic stem cells, differentiation of cardiomyocytes was inhibited by 
valproate in a dose-dependent manner (Na et al., 2003). Moreover, valproate inhibited the 
differentiation of embryonic heart cells by reducing the contractile activity in chick heart 
micromass and D3 mouse embryonic stem cell-derived cardiomyocytes in vitro (Ahir and Pratten, 
2011). Although the parameters we were able to measure in cardiovascular disruption were 
limited (formation of thrombi, delay in vessel circulation and reduced heart rate), we expect that 
these defects in Japanese rice fish are the result of inhibition of angiogenesis (Michaelis et al., 
2004).  
Healthy cardiovascular development plays an important role in the successful hatch. 
Therefore, Japanese rice fish embryos that were able to hatch needed to have well-developed 
circulatory vessels and normally developed blood circulation. Hatching efficiency is also dose 
and developmental-stage specific. Embryos treated with higher concentrations of VPA had less 
possibility to hatch. Embryos treated with VPA at early developmental stages were asssociated 
with decreased incidence of hatching. The Japanese rice fish hatchlings developed yolk edema, 
bent tails, and reduced body length after valproate exposure. These changes are believed to be 
analogous to the spinal anomalies observed in human children with FVS. 
Our analyses of craniofacial cartilages indicate that valproate induced a phenomenon of 
microcephaly in Japanese rice fish (Table 7). We noticed that although B and C group embryos 
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have higher LC50 values of valproate compared to group A, the successful hatching of these 
embryos (B and C) was not seen in those treated with concentration of VPA greater than 10 mM. 
This indicates that the morphogenesis of the embryos treated with concentrations of VPA greater 
than 10 mM was significantly affected by sublethal concentrations of valproate. Therefore we 
have analyzed the cartilages of the neurocranium and splanchnocranium of those embryos that 
hatched successfully (Table 7). The embryos of two treatment groups (Table 5), group E: 0-2 dpf 
VPA (without circulation) or group L: 4-6 dpf VPA (with circulation), were preserved in 4% PFA 
within 24 h of hatching and stained with Alcian Blue (Hu et al., 2009). Previously, the 
preservation of hatchlings was done at 10 dpf, and if an embryo hatched earlier (in our culture 
conditions the embryos initiate hatching after 7 dpf), they were maintained in hatching solution 
without food until 10 dpf (Hu et al., 2009). In the present experiment, to avoid post hatch growth, 
we preserved the embryos within 24 hrs of hatching.  We observed that the measured length of 
the neurocranium and other cartilages in control hatchlings (untreated embryos) were 
significantly shorter than those we reported in our previous studies (Hu et al., 2009), since our 
previous studies measured cartilages in Japanese rice fish on 10 dpf. Our current data indicate 
that valproate significantly reduced the linear length of the neurocranium in both groups E and L 
embryos when compared with controls. Epidemiological studies also showed that children 
exposed to valproate prenatally have microcephaly (Almgren et al., 2009). However, 
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macrocephaly not microcephaly is considered as the most consistent phenotypic feature of 
autism spectrum disorder (ASD). To find VPA-sensitive neurocranial and/or splanchnocranial 
features, we have extended our investigation to 6 individual cartilages in the neurocraniuam (TC, 
ABC, EB, PC, AOC, BP) and 11 individual cartilages in the splanchnocranium (MC, QU, BH, 
CH, BB 1-3, BB4 and 5 CBRs). We found that compared to controls the linear lengths of TC, EB, 
AOC and BP in the neurocranium and QU, CH, and BB1-3 in the Splanchnocranium were 
significantly reduced in group E hatchlings exposed to 2 mM valproic acid during embryonic 
development (Table 7). It was also shown that, compared to controls, the linear lengths of PC in 
the neurocranium and QU, CH, BB 1-3, and CBR 1-5 in the splanchnocranium were reduced in 
group L hatchlings exposed to 2 mM valproic acid during embryonic development. Therefore, it 
appears that the reduction in the linear length of the neurocranium is the result of cumulative 
reductions of the component cartilages.  
The third aim of this study was to find an affected molecular marker of FVS and/or ASD. 
For that, we have analyzed mRNA expression levels of nine genes (catalase, gst, gr, nlgn3b, otx2, 
wnt1, iro3, shh and ccna2) in Japanese rice fish embryos at three developmental stages (Table 4) 
exposed for 48 hrs to two different concentrations of valproic acid (for group A, 1 and 2 mM, for 
groups B and C, 2 and 5 mM) (Wu et al., 2012). The selected genes belong to three categories; 
oxidative stress (catalase, gr and gst), neurogenesis (nlgn3b, Iro3, wnt1 and otx2) and regulation 
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of cell division (cyclin a2 and shh). The expression of many of the selected genes has been 
shown to be altered by valproate in human and rat (Graf et al., 1998; Bambini-Junior et al., 2011: 
Tung and Winn, 2011). Analysis of mRNA was done by rRT-PCR (Hu et al., 2008) using β-actin 
as internal control (Wang et al., 2006; Wu et al., 2008; 2011). The oxidative stress-related genes 
(gst, gr, and catalase) have been shown to be constitutively expressed in Japanese rice fish 
during development (Wu et al., 2011). Although oxidative stress is a potential cause of 
teratogenesis, surprisingly, compared to controls, we did not find any significant alteration in the 
mRNA expression pattern of catalase, gr and gst mRNA in Japanese rice fish embryos due to 
exposure to valproate at any stage of development (Figure 15). Epileptic children exposed to 
VPA also displayed no significant alterations in serum levels of catalase (Peker et al., 2009). 
Therefore, it appears that valproate-induced teratogenesis in Japanese rice fish is mediated 
through genes other than those that participate in mediating the process of oxidative stress.  
As valproate is able to induce neural tube defects in human embryos, we have analyzed 
the mRNA expression patterns of five genes (nlgn3b, iro3, wnt1, otx2, shh) that are expressed in 
the brain of Japanese rice fish embryos. Neuroligins (nlgn) are a family of postsynaptic 
cell-adhesion molecules that play roles in synaptic maturation through association of their 
presynaptic partners the neuroxins (nrxn) (Ichtchenko et al., 1995; 1996). Our data indicate that 
expression of nlgn3b mRNA is developmentally regulated in Japanese rice fish and tended to be 
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reduced in all valproate-treated groups compared to the corresponding controls. Valproate 
modulates the gene expression patterns of nlgn and nrxn in mice (Kolozsi et al., 2009). Iro3 
belongs to Iroquois family of homeoproteins and is constitutively expressed in vertebrates, flies, 
and nematodes (Gomez-Skarmeta and Modolell, 2002). In zebrafish, Iro3 has been indicated to 
inhibit formation of motoneurons and to facilitate formation of interneurons (Lewis et al., 2005). 
However, our analysis by rRT-PCR indicated that the expression of iro3 mRNA in Japanese rice 
fish is constitutive and remained unaltered either during development or after valproate exposure 
(Figure 16.4). This suggests that iro3 is not a potential target of valproate in Japanese rice fish 
embryogenesis.  
Our analysis of mRNA expression of shh, wnt1 and otx2 showed that the mRNA 
expression levels of wnt1 and otx2 genes were significantly reduced only in B group (1-3 dpf 
exposure) embryos treated with 5 mM VPA. In the other two treatment groups (A and C), these 
mRNAs remained unaltered. Shh was significantly reduced in group A (2 mM), and in the other 
groups (groups B and C) it remained unaltered. The developmental stage specific response of 
these genes cannot be explained properly from this study. However, available literature indicates 
that the teratogenic effects of valproate are also mediated by wnt1 signaling molecules 
(Shimshoni et al., 2007). Shh played a central role in cell proliferation, differentiation and 
patterning by activating the hedgehog signaling pathway. Polydactyly/arhinencephaly (Pdn/Pdn) 
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mice exposed to valproate during gestation have exencephaly, but shh mRNA content remained 
unaltered (Maekawa et al., 2005). Otx2 is recognized as an early head-domain marker (Bliz and 
Cho, 1995; Pannese et al., 1995). Microarray analysis in mouse embryos exposed to valproate 
prenatally identified several genes including otx2 as potential target genes of valproate-induced 
teratogenesis (Kultima et al., 2010). In Japanese rice fish, further studies are needed to 
understand the mechanisms of wnt1, shh and otx2 regulation by valproate. 
Our data further indicate that ccna2 mRNA expression during embryogenesis of Japanese 
rice fish was reduced by valproic acid in a developmental stage and dose specific manner. The 
cyclins and their cyclin-dependent kinase partners (CDKs), are the basic components of the 
machinery that regulates the passage of cells through cell cycle. Cyclin A2 deficiency is marked 
by early embryonic lethality. Valproate is able to downregulate cyclin A expression in gastric 
carcinoma cell lines (Zhao et al. 2011). Therefore, abnormality in cell division due to disruption 
in ccna2 expression probably is the partial reason to explain the developmental delay and 
reduced hatching efficiency by valproate as we observed in our model.  
Although the molecular endpoints are not established from this study, the present 
investigation indicates that some of the consequences of damages induced by valproate such as 
organ-specific effects in heart and blood vessels, dysmorphogenesis in neurocranial cartilages, 
and modification in neuronal gene expression, in Japanese rice fish are parallel with other 
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organisms such as zebrafish and have potential to provide an opportunity to use the Japanese rice 
fish as a model to study FVS and ASD.  
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CHAPTER 5 
CONCLUSIONS AND FUTURE WORKS 
In this study, the Japanese rice fish was considered as a unique non-mammalian vertebrate 
model to study VPA teratogenesis. The higher the concentration of VPA in each group, the more 
incidence of death happened. The calculated LC50 value of group A (treatment during 0-2 dpf) 
was 1.68 ± 1.55 mM, which was much lower than that of group B (treatment during 1-3 dpf; LC50 
for group B was 26.45 ± 1.64 mM ) or group C (treatment during 4-6 dpf; LC50 for group C was 
20.37 ± 3.3 mM). VPA has deleterious effects on cardiovascular development. The experiments 
manifested that VPA reduced heart rates, increased incidence of thrombus and inhibited onset of 
circulation in each group. VPA also decreased hatching efficiency, and resulted in axial 
malformations. Yolk edema and curved spinal cord were viewed on hatchlings treated with VPA 
prenatally. The higher the concentration of VPA the embryos were treated with, the more severe 
the effects were. The earlier the exposure, the more dangerous the VPA treatments were. In 
addition, VPA caused deformed craniofacial cartilages. The length of the neurocranium, quadrate, 
ceratohyal and basibrancials 1-3 was reduced in both groups E (0-2 dpf) and L (4-6 dpf). 
Trabeculae, epiphyseal bar, anterior orbital cartilage and basilar plate displayed reduction of
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length only in group E (0-2 dpf). Polar cartilage and ceratobranchials 1-5 become shorter only in 
group L (4-6 dpf). However, anterior Basicranial commissure, meckel's cartilage, basihyal and 
basibrancial 4 remained unaltered. While there are no conclusive outcomes of craniofacial 
cartilages drawn from this study, most of the neurocranial and splanchnocranial cartilages were 
modified by VPA. If the neurocranial or splanchnocranial cartilage became malformed through 
VPA treatment, the length of it would be reduced. The experiments revealed that VPA induced the 
abnormal morphological features (yolk edema, bent tails and microcephaly) in the hatchlings, and 
the embryos at early developmental stages are more sensitive to VPA toxicity. Some genes (gst, gr 
and catalase) that were indicated to be involved in oxidative stress remained unaltered in VPA 
treated-embryos, however, the expression levels of some genes (nlgn3b, otx2, wnt1) correlated 
with neurodevelopment were modified only in 5 mM VPA-treated embryos of group B (1-3 dpf). 
Shh and cyclin A2 are associated with cell division, and their expression levels were all reduced in 
embryos treated with 2 mM VPA at the early developmental stage (group A, 0-2 dpf). The early 
developmental stage (0-2 dpf) is known to be a very crucial period for cell division. Hence, shh 
and cyclin A2 were indicated to be implicated in the VPA-induced teratogenesis, e.g. neural tube 
defects, by interrupting continuation of cell cycles. The teratogenic features of Japanese rice fish 
induced by VPA were analogous to those of human FVS. In addition, all of these available 
characteristics which could be regarded as parameters of FVS evaluation have potential to validate 
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this Japanese rice fish as a certified and beneficial model to study VPA-induced teratogenesis, 
even though more intensive investigation is needed to complete this validation.  
Several problems remain unsolved from this study. These provide some additional 
directions for future investigation. Most Children affected with FVS have neurodevelopmental 
disorders and show autistic-like behaviors, affecting the cognitive, verbal and communicative 
abilities. Autism spectrum disorder (ASD) is behaviorally defined, and therefore any 
neurodevelopmental disorders displaying autistic-like behaviors will be attributed as ASD. The 
Japanese rice fish can further be used to detect their behaviors induced by VPA to evaluate their 
potential as a model to study ASD. Epidemiological studies report the ratio of males to females 
diagnosed with autism spectrum disorder (ASD) is 4.3: 1.0 (Fombonne, 2003) and the molecular 
mechanism of this phenomenon is as yet unknown. Thus, scientists can concentrate on the 
epigenetic modification of genes, such as Dmy, to study the gender specific induction of ASD. 
Dmy (dmrt1bY; DM-domain gene on the Y chromosome), the male determining gene, is only 
found in Japanese rice fish (Oryzias latipes) (Matsuda et al., 2002, 2003) and its nearest relative 
Oryzias curvinotus (Kondo et al., 2003).  
In our study, we did not establish detailed and specific molecular endpoints. However 
several genes were suggested to be involved in the pathogenesis of FVS induced by VPA. In the 
future, it will be desirable to do real-time reverse transcription PCR to test the expression patterns 
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of these genes by quantifying their mRNAs. In addition, it will be desirable to do in situ 
hybridization to detect the locations of these genes and to measure their expression levels. 
Although we hypothesize that oxidative stress induced by VPA results in the pathogenesis of FVS, 
there were no alterations in the oxidative stress related genes (gst, gr, catalase) that we evaluated in 
this study. In future, it will be desirable to determine whether other pathways related to oxidative 
stress are affected. Consequently, lipid peroxidation and the ratio of NAD+: NADH which are 
indicators of the redox state of a cell, are proposed as potential test parameters. 
From this study we have established that most neurocranial and splanchnocranium 
cartilages were affected by VPA. Neural crest (NC) cells are the precursors of these cartilages. 
Many signal molecules, such as sonic hedgehog (shh), fibroblast growth factor (fgf), Wingless 
(wnt) and Notch, are associated with the migration of NC cells from the CNS. Therefore, in the 
future, investigations on these signaling molecules and their alterations by VPA are necessary. 
Until now only one medication, risperidone, has been approved by the Food and Drug 
Administration (FDA) of the USA for the pharmacologic management of autistic-like behaviors in 
Children. After establishing this animal model, we can further our research to test the ability of 
some natural products, such as Ginseng and Ginkgo biloba, as potential preventive agents for the 
FVS and/or ASD (autism spectrum disorder). It is promising that some natural products are more 
effective with less side effects.  
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